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Satellite cells are muscle stem cells that are responsible for the growth and repair of 
skeletal muscle tissue.  Satellite cells typically exist in a quiescent state in their niche 
between the sarcolemma and basal lamina.  In response to muscle tissue injury, activated 
satellite cells, otherwise known as myoblasts, migrate to the site of injury where they 
proliferate and subsequently differentiate and fuse to repair damaged myofibers.  The 
success of muscle growth and repair is highly dependent on the speed and degree to which 
these myoblasts migrate, proliferate and differentiate.  This overall process, referred to as 
myogenesis, is largely controlled by the myogenic regulatory factors, a group of basic helix-
loop-helix transcription factors including MyoD, Myf5, myogenin and Mrf4.   It has 
recently been found that the Wnt family of secreted signalling proteins are highly involved 
in the regulation of developmental processes such as myogenesis.  Wnt proteins are a 
family of 21 highly-conserved, secreted, cysteine-rich signalling molecules which are found 
in all multi-cellular organisms.  Wnt signalling is highly versatile and is initiated by the 
binding of extracellular Wnt to cell-surface Frizzled receptors (Fz).  It is highly dependent 
on both the Wnt isoform and Fz type and may initiate one of three known signalling 
pathways.  Wnt3A and Wnt7A are of particular interest as they have previously been 
linked with myogenesis.  C2C12 myoblasts over-expressing Wnt3A have been seen to have 
reduced levels of motility and terminal differentiation.  Wnt7A is suspected to maintain a 
healthy satellite cell pool by regulating self-renewal; injection of recombinant Wnt7A into 
mouse leg muscle resulted in increased satellite cell numbers.  In vitro Wnt studies have 
typically involved the treatment of mouse cells with conditioned medium containing Wnt, 
often at unknown concentrations.  In our study we wished to test the effects of known 
concentrations of recombinant Wnt3A and Wnt7A on mouse C2C12 and donor-derived 
human skeletal muscle myoblasts (HSkM) in vitro.  Wnt3A and Wnt7A were seen to 
increase the rate of C2C12 migration in a dose dependent manner.  HSkM cells treated 
with 10 ng/ml Wnt3A also displayed increased motility.  Neither Wnt3A nor Wnt7A were 
seen to have any significant effects on the proliferation of C2C12 or HSkM cells.  Wnt3A 
(10ng/ml and 100 ng/ml) but not Wnt7A was seen to decrease C2C12 terminal 
differentiation as measured by expression of myosin heavy chain (MyHC).  Subsequent 
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confocal microscopy revealed that Wnt3A significantly reduced the percentage of MyoD+ 
C2C12 nuclei during differentiation.  A reduction in nuclear MyoD would support the 
observed impaired commitment to differentiation.  However, donor-derived human 
skeletal muscle myoblasts treated with 10 ng/ml Wnt3A were not seen to have significantly 
reduced nuclear MyoD levels or terminal differentiation; the reason for this is unclear but 
may relate to a number of factors including the concentration of Wnt, Fz and co-receptor 
profiles and the presence of specific extracellular matrix and serum factors.  These studies 
provide new insight into the role of Wnts in myogenesis and lay the foundation for future 
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1.1 Adult Skeletal Muscle Tissue 
Adult mammalian skeletal muscle tissue contains a large population of nuclei which are found 
within the myofiber structure (Cornelison and Wold, 1997; Charge and Rudnicki 2004).  It has 
been shown that these myonuclei are terminally differentiated following myoblast fusion to 
myotubes (Hawke and Geary, 2001; Le Grand and Rudnicki, 2007).  Therefore, these post-
mitotic myonuclei are unable to proliferate and facilitate the growth and repair of existing muscle 
tissue.  A population of precursor cells, known as satellite cells, exist within skeletal muscle 
tissue and are charged with the growth and repair of muscle fibers (Hawke and Geary, 2001; Le 
Grand and Rudnicki, 2007).  The ability of these cells to differentiate and form new myofibers, 
suggests that they are part of the adult stem cell family.   
1.1.1 Satellite cells – Identification 
Satellite cells were first identified in frog leg muscle (Mauro, 1961).  Initially these cells could 
only be identified by their morphological characteristics and location within the muscle tissue.  
They were seen to lie in a quiescent state in a niche between the sarcolemma and basal lamina 
along all muscle fibers (Mauro, 1961; Charge and Rudnicki 2004) (Figure 1.1).  Skeletal muscle 
satellite cells display a relatively high nucleus-to-cytoplasm ratio and contain very few 
organelles (Hawke and Garry, 2001). The satellite cell nuclei are also of a smaller size than the 
myonuclei of the myofibers (Hawke and Garry, 2001).  An increase in the amount of 
heterochromatin can be found within these cells when compared to terminally differentiated 
myonuclei (Charge and Rudnicki, 2004, Schultz and McCormick, 1994).  The morphological-
based identification process is however slow and tedious; a number of satellite cell markers have 
subsequently been identified.  Satellite cells are CD45− (a signalling molecule involved with cell 
growth and differentiation) and are positive for M-cadherin (cell adhesion molecule), Myf5 
(myogenic regulatory factor), saliomucin CD34 (cell-adhesion molecule) as well as Pax3 and 
Pax7 (myogenic transcription factors) (Irintchev et al., 1994; Beauchamp et al., 2000; Sherwood 
et al.,2004; Kassar-Duchossoy et al., 2005; Relaix et al., 2005).  The Pax7 transcription factor is 
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the most commonly used marker of satellite cells in skeletal muscle tissue (Tajbakhsh et al. 
1997; Beauchamp et al. 2000; Shefer et al. 2006) (Figure 1.1).   
Figure 1.1 Localization of satellite cells within adult skeletal muscle. Skeletal muscle satellite cells occupy a 
unique niche within the muscle tissue. A) A longitudinal view of muscle tissue showing a satellite cell (SC) between 
the basal lamina (BL) and the plasma membrane (PM) of the myofiber structure.  Post-mitotic myonuclei (MN) lie 
within the muscle fiber structure. B) A murine satellite cell labelled with anti-Pax7 antibodies (red-nuclei) can be 
seen along the muscle fiber which also stains positive for the structural protein caveolin-1 (green).C) DAPI nuclear 
staining of the muscle tissue reveals both the satellite cells and post-mitotic myonuclei within the muscle fiber.  
Constructed using references: Mauro, 1961; Charge and Rudnicki, 2004; Relaix and Zammit, 2012. 
 
1.1.2 Satellite cells – The Myogenic Process 
Satellite cells typically reside in a dormant/quiescent state and are activated by stress as a result 
of strain or trauma to the muscle tissue (Charge and Rudnicki, 2004).  Activated cells derived 
from satellite cells, known as myogenic precursor cells or skeletal myoblasts, then migrate to the 
site of the muscle trauma where they undergo numerous rounds of replication before 
differentiation and fusion to produce multinucleated myofibers (Le Grand and Rudnicki, 2007; 
Burdzinska et al. 2008).  During this process of myogenesis there is an up-regulation of 
myogenic regulatory factors (MRFs) such as MyoD, Myf5, myogenin and Mrf4 (Fuchtbauer and 
Westphal 1992; Burattini et al.,2004; Holterman and Rudnicki 2005) (Figure 1.2). These 
transcription factors facilitate the expression of structural proteins such a myosin heavy chain 
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(MyHC) and consequently terminal differentiation (Zammit et al.,2004; Kuang et al.,2006; Le 
Grand and Rudnicki, 2007).  MyoD and Myf5 are vital for myogenic commitment of satellite 
cells while myogenin and Mrf4 are required for terminal differentiation and fusion (Seale and 
Rudnicki, 2000).  Skeletal myoblasts that do not undergo fusion return to quiescence to replenish 
the satellite cell population (Kuang et al., 2007) (Figure 1.2).  This process is vital to maintain 
the population of satellite cells (Cornelison and Wold, 1997; Tajbaksh, 2005).  Both Pax3 and 
Pax7 have been shown to be major regulators of satellite cell self-renewal and differentiation 
(Kuang et al.,2006).  The up-regulated expression of Pax7 acts to maintain the quiescent state of 
satellite cells, whereas down-regulation is accompanied by cellular differentiation (Cornelison 
and Wold, 1997; Tajbaksh, 2005) (Figure 1.2).  It has recently been documented that the 
expression of the various MRFs and ultimately the processes of satellite cell migration, 
proliferation and differentiation during myogenesis is largely controlled by Wnt signalling 
proteins (Brack et al., 2008; Bentzinger et al., 2012). 
 
Figure 1.2 Protein expression during satellite cell activation, proliferation and differentiation.  Pax7 is 
expressed by quiescent satellite cells and at reduced levels in activated satellite cells.  An increase in Pax7 
expression causes activated satellite cells to return to a quiescent state.  MyoD and Myf5 are expressed as satellite 
cells become activated, start to proliferate and differentiate.  Myogenin is up-regulated during differentiation and 
fusion of myoblasts.  The structural protein, MyHC is produced during the formation of new myofibers.  




1.2 Stages of Myogenesis 
1.2.1 Activation 
The initial activation of satellite cells leads to the reduced expression of Pax7 and the increased 
expression of Myf5 and MyoD (Cornelison and Wold, 1997, Tajbakhsh, 2005). This activation is 
accompanied by the ubiquitylation and breakdown of Pax3, which has been linked with cell 
commitment and the progression of myogenesis (Boutet et al., 2007).  Activated satellite cells, 
termed myoblasts, then move to the site of injury.   
1.2.2 Migration 
Cellular migration is essential for the development, growth and repair of tissues.  In muscle 
tissue, myoblasts are able to move along the myofiber to the site of an injury, replicate, align and 
then fuse and repair the damaged tissue.  Chemokines released by injured and surrounding 
myoblasts play an important role in controlling migration (Griffin et al.,2010).  These 
chemokines include fibroblast growth factor (FGF), hepatocyte growth factor (HGF), platelet-
derived growth (PDGF) and interleukin-4 (Robertson et al.,1993; Bischoff, 1997; Lafreniere et 
al.,2006).  In addition to the various chemokines, myoblast migration is largely dependent on a 
group of cell surface proteins known as integrins (Friedl and Brocker, 2000).  Integrins are the 
most prominent and well characterized trans-membrane receptors involved with the linkage of 
contractile actin and extracellular matrix (ECM) ligands during cell migration (Hynes, 2002).  
Integrins are αβ heterodimers consisting of a large, cell surface ECM binding domain and 
relatively short cytoplasmic tail which is linked to the actin cytoskeleton (Hynes, 2002).  The 
areas at which the cell is anchored to the ECM via integrin binding are known as focal adhesions.  
Activated Rho-associated, coiled-coil containing protein kinase 2 (ROCK2) helps to modulate 
the formation of these focal adhesion points while the membrane associated cytoskeletal protein 
vinculin physically links integrins to the actin cytoskeleton of the cell (Bakolitsa et al.,2004; 
Gallant et al.,2005; Burridge et al.,1990) (Figure1.3).  The initial stage of migration involves the 
formation of hand-like structures called lamellipodia which are formed by the distortion of the 
leading edge of the cell (Figure 1.3).  The formation and extension of the lamellipodia involves 
actin polymerization which is regulated by members of the integrin family as well as cell surface 
proteoglycans (Humphries et al.,2006; Huttenlocher and Horwitz, 2011).  The lamellipodia then 
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reach forward in the direction of movement and adhere to the ECM via integrin-based adhesion 
points (Friedl and Wolf, 2010; Huttenlocher and Horwitz, 2011).  Actin myofibers within the 
main body of the cell then contract as integrins at the trailing edge of the cell detach from the 
ECM, and the cell pulls itself forward.  Cellular actin fibers contain contractile myosin-motors 
which are regulated by the GTPase family.  Rho/ROCK signalling is thought to mediate the 
retraction of the trailing edge and possibly cell detachment (Webb et al., 2004).  Integrins from 
the detached trailing end undergo endocytosis and are recycled to the leading edge of the cell 
(Huttenlocher and Horwitz, 2011).  During forward movement, the cell will adapt 
morphologically to the ECM in an effort to take the path of least resistance.  In addition, 
myoblasts are able to degrade the ECM, allowing for easier movement towards the site of injury.  
This degradation involves the proteolysis of ECM factors by cell-surface serine and metallo-
proteinases.  These include membrane type-1 matrix metalloproteinase (MT1-MMP) and matrix 
metalloproteinase-2 (MMP-2)which break down any ECM structures blocking forward migration 
(Ohuchi et al., 1997).The specificity of integrin binding is determined by the extracellular 
domain which allows for the binding to ECM factors such as fibronectin, collagen and laminin 
(Friedl and Brocker, 2000; Huttenlocher and Horwitz, 2011).  Myoblast cells tend to utilize 
integrin-dependent migration. The variability in the extracellular domain of integrins means that 
motility dynamics are determined both by a cell’s integrin profile as well as ECM components 
(Huttenlocher and Horwitz, 2011).  Alternatively, during integrin-independent migration, the 
extracellular matrix is left relatively unchanged as the cell moves quickly over the ECM using 







Figure 1.3 Integrin-dependent migration of skeletal muscle myoblasts.  Integrins accumulate at the leading edge 
of the cell, followed by the extension of lamellipodia and attachment to the ECM.  Actin fibers within the main cell-
body contract as the trailing edge of the cell detaches from the ECM, pulling the cell forward.  ROCK2 mediates the 
detachment of the trailing edge of the cell as well as formation of new focal adhesion sites.  The cytoskeletal protein 
Vinculin links integrins at the focal adhesion points to cytoskeletal actin.  Breakdown of ECM components by the 
proteinases MT1-MMP and MMP-2 allows for unimpeded movement through the matrix.  Constructed using 
references: Ohuchi et al., 1997; Humphries et al., 2006; Huttenlocher and Horwitz, 2011. 
1.2.3 Proliferation 
The proliferation of activated myoblasts at the site of an injury is largely regulated by 
cytokines/growth factors that are secreted by macrophages and the myoblasts themselves 
(Hawke and Geary, 2001; Vitello et al., 2004).  Macrophages are drawn to the site of injury 
where they envelope tissue debris and secrete growth factors which encourage proliferation of 
myoblasts (Hawke and Geary, 2001; Vitello et al.,2004).  These growth factors include insulin-
like growth factor-1 (IGF-I), IGF-II, fibroblast growth factor (FGF), hepatoctye growth factor 
(HGF), leucocyte inhibitory factor (LIF), interleukin-6 (IL-6) and the transforming growth 
factor-β (TGF-β) (Table 1.1).  These chemokines in turn activate the expression of the myogenic 
regulatory factors (MRFs).  An increase in the expression of the MRF, Myf5 has been shown 
increase the rate of myoblast proliferation (Cornelison and Wold, 1997; Tajbakhsh, 2005).  The 
return of activated satellite cells to a quiescent state has been associated with a reduction inMyf5 
and MyoD expression and an increase in Pax7 expression (Cornelison and Wold, 1997; 
Tajbakhsh, 2005).  This process of self-renewal is vital for the upkeep of the satellite cell 
population.  Conditions such as muscular dystrophy are characterized by a dwindling of the 















Table 1.1 The effect of secreted growth factors on myoblast proliferation and 
differentiation 
Factor/s Secreted by Effect  Reference 
IGF-I, IGF-II macrophages, myoblasts proliferation ↑ 
differentiation ↑ 
 
Hawke and Geary, 2001; 
Vitello et al.,2004 
FGF macrophages, myoblasts proliferation ↑ 
differentiation ↓ 
 
Hawke and Geary, 2001; 
Vitello et al.,2004 
HGF macrophages, myoblasts proliferation ↑ 
differentiation ↓ 
 
Hawke and Geary, 2001; 
Vitello et al.,2004 
TGF-β macrophages, myoblasts proliferation ↑ 
differentiation ↓ 
 
Hawke and Geary, 2001; 
Vitello et al.,2004 
IL-6 macrophages proliferation ↑ 
 
 
Hawke and Geary, 2001 
LIF macrophages proliferation ↑ 
 
Hawke and Geary, 2001 
1.2.4 Differentiation and fusion 
Differentiation of skeletal muscle myoblasts is a highly controlled process which involves; 1) the 
expression of muscle-specific regulatory factors, 2) exit from the cell cycle and 3) expression of 
contractile muscle proteins (Moran et al., 2002).  During the first step of differentiation, there is 
an up-regulation of the expression of the four MRFs; MyoD, myogenin, Mrf4 and Myf5 
(Fuchtbauer and Westphal 1992; Moran et al., 2002; Holterman and Rudnicki 2005).  These 
muscle-specific MRFs interact with themyocyte enhancer factor 2 (MEF2) family of MADS box 
transcription factors and initiate production of muscle structural proteins via the E-box and 
MEF2 promoter regions (Moran et al., 2002).  The second step of differentiation involves the 
irreversible withdrawal of myoblasts from the cell cycle (Moran et al., 2002; Joulia et al, 2003).  
This progression through the cell-cycle is regulated by the activation and inhibition of 
phosphoproteins by cyclin-complexed kinases (Moran et al., 2002).  These cyclin-kinase 
complexes are in turn controlled by cyclin-dependent kinase inhibitors (CK1) (Moran et al., 
2002).  Contractile motor proteins such as myosin are produced during the third step of 
differentiation.  Myosins consist of smaller subunits, including myosin heavy chain (MyHC) and 
give skeletal muscle its contractile ability (Weiss and Leinwand, 1996; Maccatrozzo et al., 
2007).  Successful progression through differentiation leads to the fusion and formation of multi-
nucleated myotubes and thus the growth and repair of the muscle tissue.    
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1.2.4.1 Myf5 and MyoD 
Myf5 and MyoD are both members of the basic helix-loop-helix (bHLH) family of myogenic 
transcription factors (Joulia et al, 2003; Holterman and Rudnicki 2005).  As with all members of 
the MRF family, Myf5 and MyoD form heterodimers with ubiquitous bHLH E-proteins 
(Sartorelli and Caretti, 2005).  Formation of these heterodimers is required for DNA-binding and 
activation of target genes(Sartorelli and Caretti, 2005).  Gene knockout experiments performed 
in mice suggest that MyoD initiates myoblast lineage commitment by up-regulating myogenin 
and Mrf4 expression, whereas Myf5 up-regulates myoblast proliferation (Le Grand and 
Rudnicki, 2007, Ustanina et al., 2007).  Further gene knockout studies have also revealed the 
functional redundancy that exists within the MRF signalling pathways (Rudnicki and Jaenisch, 
1995; Kablar et al., 1997; Chanoine et al., 2004).  Mice lacking a functional MyoD gene have 
been observed to have no physical abnormalities, but express four-fold higher levels of Myf5 
(Megeney et al.,1996).  It is suspected that Myf5 is able to compensate in part for the absence of 
MyoD.  Despite this compensation, the rate of differentiation in MyoD-knockout myoblasts is 
decreased.  Mice lacking a functional Myf5 gene show a four-fold increase in MyoD expression 
and no physical abnormalities (Megeney et al.,1996).  However, mice lacking both the MyoD 
and Myf5 genes have severe abnormalities and lack myoblasts (Ustanina et al., 2007).Since 
MyoD and Myf5 are expressed relatively early in the differentiation process, these two MRFs are 
commonly used to investigate the onset/activation of differentiation.  Following MyoD andMyf5 
expression, Myogenin and Mrf4 are up-regulated, leading to terminal myoblast differentiation 
and fusion into myofibers (Charge and Rudnicki, 2004).  It is apparent that the expression of 
MyoD and Myf5 is essential for rapid myogenesis.  
1.2.4.2 MyHC 
Myosin is a eukaryotic, adenosine triphosphate (ATP) driven motor protein which interacts with 
actin to produce cellular movement such as muscle contraction (Weiss and Leinwand, 1996).  
Myosin is typically found as a hexameric protein and is made up of two 200kDa myosin heavy 
chain (MyHC) subunits and two pairs of 17-23 kDa, non-identical light chain subunits (MyLC) 
(Rayment et al., 1993; Weiss and Leinwand, 1996; Maccatrozzo et al., 2007) (Figure 1.4).  It is 
the myosin heavy chain (MyHC) subunits that give myosin its contractile and filament-forming 
abilities, making MyHC the quintessential skeletal muscle marker (Weiss and Leinwand, 1996; 
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Maccatrozzo et al.,2007; Quintin et al., 2008).  The MyHC subunit can further be divided into 
two domains; a globular, N-terminal domain/head, responsible for contraction, and an alpha-
helical coiled-coil carboxyl domain which allows for filament formation (Weiss and Leinwand, 
1996; Maccatrozzo et al.,2007) (Figure 1.4).The two non-identical light chain subunits are 
referred to as the ‘essential’ and ‘regulatory’ light chains (MyLC-1 and MyLC-2 respectively) 
and bind to the neck region of the MyHC subunit (Rayment et al.,1993).  The regulatory light 
chain (MyLC-2) is actively involved during muscle contraction where it is phosphorylated by 
myosin light chain kinase (MyLCK), resulting in a conformational change of the globular head 
and contraction (Morano et al.,1997).  The exact role of the non-phosphorylatable essential light 
chain (MyLC-1) is not known, but it is suspected that the subunit contributes to the stability of 
the myosin structure (Morano et al.,1997). Nine mammalian isoforms of MyHC have been 
identified in striated cardiac and skeletal muscle fibers and show a high level of interspecies 
identity (Berg et al.,2001; Maccatrozzo et al.,2007). 
 
Figure 1.4 Myosin structural motifs.  The hexameric myosin motor protein consists of two heavy (MyHC) and 
four light (MyLC) myosin chain subunits.  The two heavy chain subunits contain an N-terminal, globular head, 
involved with contraction, and a filament-forming C-terminal, alpha-helical coiled-coil domain.  Two non-identical 
MyLC subunits referred to as the ‘essential’ and ‘regulatory’ myosin light chains (MyLC-1 and MyLC-2 
respectively), are bound to the neck of each MyHC subunit.  The MyLC subunits are involved with contraction and 
maintaining the structural stability of the myosin protein. Constructed using references: Weiss and Leinwand, 1996; 













Being a motor protein, MyHC is expressed only in differentiated myoblasts.  For this reason, 
MyHC can be used to determine the degree to which a population of myoblast cells has been 
terminally differentiated. 
1.3 Wnt Signalling proteins 
Wnt proteins are a family of at least 21 highly-conserved, secreted, cysteine-rich, lipid-modified, 
glycoproteins that are involved in a multitude of developmental and physiological processes 
(George-Weinstein et al.,1998; Cadigan and Liu, 2006; Maiese et al., 2008).  Wnt proteins are 
found in all multi-cellular organisms and act to regulate numerous stages of development, from 
patterning of the embryo and production of tissues and organs, to the regulation of cell 
migration, axon guidance and polarity (He et al.,2004;Cadigan and Liu, 2006; Endo et al.,2005; 
Nusse, 2008).  In recent years it has been suggested that the Wnt proteins are important 
regulatory factors in migration, proliferation and lineage specification in a number of cell types 
(Tanaka et al.,2011, Bentzinger et al., 2012).Wnt proteins interact with the seven-pass 
transmembrane receptor Frizzled (Fz) on the surface of cells and activate the expression of 
various transcription factors which in turn regulate processes including myogenesis (Peifer and 
Polakis, 2000; Huelsken and Behrens, 2002; Cadigan et al., 2005; Janda et al., 2012). 
1.3.1 Wnt structure 
Members of the Wnt gene family are characterized by their similarity to the Drosophila Wingless 
(Wg) and mouse Int-1 genes (Wodarz and Nusse, 1998).  The genes coding for Wnt proteins are 
highly conserved and code for proteins of between 350 and 400 residues (Wodarz and Nusse, 
1998; Janda et al., 2012).  Little is known about the structure of the Wnt proteins due to their 
highly insoluble nature and domains in their primary sequences not being clearly related to any 
known protein folds (Wodarz and Nusse, 1998; Janda et al.,2012).  Their hydrophobic nature is 
due to the addition of palmitate and/or palmitoleic acid to a region of conserved cysteine residues 
found in all Wnt proteins (Willert et al.,2003; Takada et al.,2006).  Despite difficulties in 
obtaining crystallized Wnt protein for crystallography, it is known that all Wnts share the 
features of a secreted protein i.e. a signal peptide, numerous potential N-glycosylation sites and a 
region of conserved cysteine residues (±22 residues) most likely involved in disulphide bond 
formation (Wodarz and Nusse, 1998).  Glycosylation of secreted proteins such as Wnts ensures 
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their stability in the extracellular environment (Sola and Griebenow, 2010).  It is thought that 
acylation of Wnts allows for intracellular trafficking as well as full activity of the secreted 
proteins (Janda et al., 2012).  A total of 19 human Wnt proteins have been characterized; they 
share 27-83% amino-acid sequence identity (Miller, 2002).  Sequencing of Wnt genes has shown 
a high level of gene conservation between species (Table 1.2).  This high level of conservation 
suggests that Wnts are vital signalling molecules and have similar functions and mechanisms of 
action between different species.   
Table 1.2 Interspecies similarity of Wnt3A and Wnt7A protein sequences 
Organisms Compared Protein Percentage identity (%) 
Human-Mouse Wnt3A 97 
Human-Rhesus monkey Wnt3A 99 
Human-Chicken Wnt3A 87 
Human-Zebrafish Wnt3A 83 
   
Human-Mouse Wnt7A 99 
Human-Rhesus monkey Wnt7A 98 
Human-Chicken Wnt7A 93 
Human-Zebrafish Wnt7A 85 
Protein sequence alignment was done using the ClustalW alignment software with sequences obtained from the 
NCBI protein databank (see Appendix II).   
1.4 Wnt signalling 
There are three different Wnt signalling pathways; 1) the well studied and understood 
canonical/β-catenin dependent pathway, and the poorly understood non-canonical/β-catenin 
independent pathways which include the 2) Ca2+ and 3) planar cell polarity (PCP) pathways 
(Huelsken and Behrens, 2002; Nusse, 2003; Packard et al., 2003; Laeremans et al., 2010; Tanaka 
et al.,2011).  Each of these pathways involves the binding of Wnt to Frizzled receptors (Fz) on 
the cell-surface leading to the activation and expression of target genes (Huelsken and Behrens, 
2002).  It has recently been established that certain Wnt proteins, including Wnt3A and Wnt7A, 
play an important role in myogenic differentiation and specification by regulation of MRFs such 
as MyoD and Myf5 (Maiese et al., 2008). 
1.4.1 Frizzled receptor  
The seven-pass transmembrane receptor Frizzled (Fz) is believed to be involved in almost all 
Wnt signalling (He et al.,2004; Huang and Klein, 2004). Wnt lipid groups bind directly to the N-
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terminal linked, cysteine rich domain (CRD) on the cell-membrane-associated Frizzled (Fz) 
receptor (Huelsken and Behrens, 2002; Janda et al.,2012).  Fz receptors are exclusive to the cell-
membrane and are often found coupled to heterotrimeric G proteins (Huang and Klein, 2004; 
Malbon, 2004; Janda et al., 2012).  A wide range of Fz isoforms and the numerous Wnt isoforms 
makes this type of signalling extremely versatile.  The frequency of these receptors on the cell 
surface has been shown to be a major rate-limiting factor in response to extracellular ligand 
(Mukai et al., 2010).  Hela cells have been seen to control the frequency of these receptors via a 
cycle of ubiquitylation and deubiquitylation, which is controlled in part by the deubiquitylating 
enzyme UBPY/USP8 (Mukai et al., 2010).  Ubiquitylation of Fz results in endocytosis which is 
then followed by recycling of the receptors to the cell surface or transportation to the lysosome 
for destruction (Mukai et al., 2010).  Deubiquitylation triggers the recycling of Fz to the cell 
membrane.    
1.4.1.1 Frizzled structure 
Frizzled proteins range in length from around 500 to 700 amino acids and contain an 
extracellular, N-terminal-linked cysteine rich domain (CRD), a membrane anchored region 
consisting of seven hydrophobic domains and an intracellular signalling region (Huang and 
Klein, 2004) (Figure1.5).  Knowledge of the structural conformation of Fz is limited and is based 
on the unbound cysteine rich domain (CRD) of Fz8 as well as the secreted CRD antagonist, 
secreted Frizzled-Related Protein (sFRP) (Janda et al.,2012).  Fz8-CRD and sFRP are ~160 
residues in length and consist largely of β-helical structures (Janda et al.,2012).  The CRD 
contains 10 conserved cysteine residues, most likely forming structurally stabilizing disulphide 
bonds (Huang and Klein, 2004).  Seven hydrophobic domains have been identified and lie 
between the CRD and intracellular C-terminus and are thought to form transmembrane α-helices 
(Huang and Klein, 2004) (Figure 1.5).  Sequence analysis of the ten identified human Fz has 
shown that the receptors fall into four main clusters; Fz1, Fz2 and Fz7 which share 75% amino 
acid identity, Fz5 and Fz8 with 70% identity, Fz4, Fz9 and Fz10 with 65% identity, and Fz3 and 
Fz6 which share 50% identity (Fredriksson et al.,2003).  A single cell may contain one or more 
types of Fz.  This Fz profile determines how specific Wnts affect the cell. 
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Figure 1.5 Proposed Frizzled protein motifs.  Extracellular Wnt binds to the cysteine rich domain (CRD) of the 
frizzled receptor (Fz).  The seven hydrophobic regions within the receptor structure form transmembrane α-helices 
(I-VII).  Wnt binding causes structural change to the intracellular signalling region which in turn leads to activation 
of relevant transcription factors. Constructed using reference: Huang and Klein, 2004 
1.4.2 Canonical signalling – β-Catenin dependent pathway 
The Wnt-mediated canonical/β-catenin dependent pathway requires the interaction of Wnt 
proteins with Fz coupled to the Low-density Lipoprotein receptor related proteins 5 and 6 
(Lrp5/6) (Peifer and Polakis, 2000; He et al.,2004; Cadigan et al., 2005) (Figure 1.6).In the 
absence of Wnt, the signalling protein Dishevelled (Dsh) is inactive, resulting in the formation of 
the β-catenin destruction complex (Jin et al., 2008).  This complex is made up of axin, glycogen 
synthase kinase-3β (GSK-3β), Casein Kinase-1 (CK1) and adenomatous polyposis coli (APC) 
(Huelsken and Behrens, 2002; Jin et al., 2008).β-catenin is phosphorylated by CK1 at serine 45 
which then allows for the phosphorylation of serine/threonine residues 41, 37 and 33 by GSK-3β 
(Huelsken and Behrens, 2002).  Phosphorylation of β-catenin targets it for ubiquitylation by β-
transducin repeat-containing protein 9 (βTrCP9) (Huelsken and Behrens, 2002; Huang and 
Klein, 2004).  Ubiquitylated β-catenin is broken down by the large protease/proteosome, which 
is modulated by the multi-subunit serine/threonine phosphatase, PP2A (Huelsken and Behrens, 
2002; Huang and Klein, 2004). As a result, Wnt target genes are not transcribed.   
When Wnt is present, it binds to the Frizzled receptor which then activates cellular Dishevelled 
protein (Dsh) and prevents the formation of a β-catenin destruction complex and subsequent 
phosphorylation of β-catenin (Hinoi et al., 2000; Peifer and Polakis, 2000; Salic et al., 2000) 
(Figure 1.6).   When Dishevelled protein (Dsh) is active, it is thought to inhibit the formation of 
the destruction complex by displacing glycogen synthase kinase-3β (GSK-3β) from axin, 
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replacing it with GBP/Frat-1 (Huelsken and Behrens, 2002).If β-catenin breakdown is inhibited, 
the protein accumulates in the cytosol and ultimately moves into the nucleus (Peifer and Polakis, 
2000). β-catenin then complexes with T-cell factor/lymphoid enhancer factor (TCF/LEF) within 
the nucleus resulting in the expression of Wnt target genes (Huelsken and Behrens, 2002; Tanaka 




Figure 1.6 Canonical/β-catenin dependent Wnt signalling pathway.  A)  In the absence of Wnt proteins, Dsh remains 
inactive, maintaining cytosolic levels of the β-catenin destruction complex.  Cytosolic β-catenin is phosphorylated by CK1 and 
GSK-3β on the destruction complex resulting in the ubiquitylation of β-catenin by β-transducin repeat-containing protein and its 
subsequent breakdown by cytosolic proteosomes.  With the breakdown of β-catenin, no Wnt target genes are expressed.  B) 
Extracellular Wnts bind to the Frizzled receptor on the cell surface, initiating the canonical/β-catenin dependent signalling 
pathway.  Dsh is activated and prevents the formation of the β-catenin destruction complex which in turn leads to a build-up of β-
catenin in the cytoplasm.  β-catenin then translocates into the nucleus, complexing with TCF/LEF, activating expression of target 
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1.4.3 Non-canonical signalling 
1.4.3.1 Planar Cell Polarity pathway 
The poorly understood Planar Cell Polarity (PCP) pathway is thought to play a pivotal role in 
cell migration, acting primarily through the activity of Dsh, the small GTPase Rho and Rho-
associated kinase (ROCK) (Huelsken and Behrens, 2002; Cadigan et al.,2005;Endo et al.,2005; 
Tanaka et al, 2011) (Figure 1.7).  The PCP pathway branches from the canonical pathway in 
terms of the function of the Dsh (Huelsken and Behrens, 2002).  Wnt binds to an uncoupled Fz 
(in the absence of LRP co-receptor) resulting in the activation of GTPase Rho by Dsh which in 
turn activates jun N-terminal kinase (JNK) (Huelsken and Behrens, 2002).  Dsh is connected to 
downstream effectors such as RhoA and Rho-associated kinase (ROCK) via the signalling 
proteinDaam1 (Huelsken and Behrens, 2002).  The activation of jun N-terminal kinase (JNK) 
causes cytoskeletal re-organization and the coordinated polarization of cells, which is required 
for processes such as migration (Cadigan and Nusse, 1997; Huelsken and Behrens, 2002; 
Cadigan et al.,2005).  This re-organization can also be directly modulated by the activation of 
Rho-associated kinase (ROCK) (Lin, 2010; Huelsken and Behrens, 2002). Although not fully 
understood, the PCP pathway is known to involve the proteoglycan knypek (Kny), and the PDZ 
molecule strabismus (Stbm).  
1.4.3.2 Calcium dependent pathway 
The Wnt/Ca2+ pathway is mediated largely by the build-up of intra-cellular calcium (Huelsken 
and Behrens, 2002; Tanaka et al.,2011). This pathway involves the binding of Wnt to Fz and 
subsequent activation of phospholipase C (PLC) and Protein Kinase C (PKC) via G-proteins 
(Huelsken and Behrens, 2002; Tanaka et al. 2011) (Figure 1.7).  Activation of Phospholipase C 
(PLC) leads to the accumulation of cytosolic calcium, activating the phosphatase calcineurin 
which in turn dephosphorylates the transcription factor NF-AT (Huelsken and Behrens, 2002).  
The activated NF-AT moves into and accumulates in the nucleus and regulates the expression of 
Ca2+ pathway genes as well as inhibiting the canonical/β-catenin dependent pathway (Huelsken 
and Behrens, 2002). 
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Figure 1.7Non-canonical Planar Cell Polarity and Ca2+Wnt signalling pathways.  A) Wnt binds to Fz in the 
absence of a LRP co-receptor, this activates Dsh to signal via Daam1 and activate the small GTPase RhoA which in 
turn activates JNK and ROCK resulting in cytoskeletal reorganization and polarization.  The membrane bound Stbm 
and Kny proteins are thought to somehow be involved in the PCP pathway.  B) Binding of Wnt causes the G 
protein-mediated activation of phospholipase C (PLC) resulting in a build-up of cytosolic Ca2+ ions.  Elevated Ca2+ 
levels increase the activity of phosphatase calcineurin which then phosphorylates the transcription factor NF-AT.  
The active NF-AT moves into and accumulates in the nucleus and pathway specific genes are expressed.  














































1.4.4 Wnt-Fz interactions 
The functional specification of Wnt proteins is difficult to establish since Wnts are able to 
engage various isoforms of Fz, resulting in a range of effects (Janda et al.,2012).  Each Fz is also 
able to interact with multiple Wnt types (Janda et al.,2012).  This pleiotropy means that Wnt 
proteins can have a wide range of effects on different cells types due to variability in Fz receptor 
profile.  Depending on the isoform of Fz, Wnts are able to act via the β-catenin dependent, PCP 
or Ca2+ pathways (Cheng et al., 2008).  For example, Wnt5a is known to signal via the canonical 
pathway in the presence of the receptor Frizzled 4 (Fz4) (Mikels and Nusse, 2006).  In the 
absence of Fz4, Wnt5A is able to signal via the non-canonical pathways, depending once again 
on the Fz receptor to which it is bound (Mikels and Nusse, 2006).  In addition to this, the 
signalling pathway initiated can be affected by the concentration of Wnt.  For instance, low 
concentrations of Wnt3A (10 ng/ml) have been shown to engage Wnt/Ca2+ signalling in human 
articular chondrocytes whereas higher concentrations (100-200 ng/ml) activate the β-catenin-
dependent pathway (Kestler and Kuhl, 2011; Nalesso et al, 2011). 
1.4.5 Inhibition of Wnts 
Wnt signalling can be inhibited by a number of secreted factors. Wnt inhibitors include Cerberus 
(Cer) and the Frizzled related protein B (FrzB) which bind to Wnt, blocking interaction with cell-
surface Fz (Hsieh, et al., 1999; Huelsken and Behrens, 2002).  The Dickkopf family of secreted 
proteins are known to be involved with embryonic development through the inhibition of Wnt 
signalling.  Dickkopf-related protein-1 (Dkk1) antagonises canonical Wnt signalling by binding 
to and blocking the LRP5/6 co-receptor (Hsieh, et al., 1999; Huelsken and Behrens, 2002).In 
conjunction with the transmembrane protein Kremen, Dickkopf may also prevent LRP 
endocytosis and coupling to Fz (Hsieh, et al., 1999; Huelsken and Behrens, 2002; Mao et al., 
2002; Semenov et al., 2005).  The Wnt target gene naked (Nkd) acts as a Wnt antagonist by 
binding to cytosolic Dsh and preventing the build-up of cytosolic β-catenin, thus preventing 
canonical Wnt signalling (Huelsken and Behrens, 2002).  Dysregulation of Wnt signalling has 





1.4.6 Wnt signalling in myogenesis 
The role of Wnt proteins during embryogenesis has been well documented. For example, Wnt1 
and Wnt3A are known to induce myogenesis in the myotome of the differentiating somite 
(Petropoulos and Skerjanc 2002; Ridgeway et al.,2000).  However, focus has shifted towards 
identifying the roles of Wnts in the formation of adult tissues such as skeletal muscle.  This 
research has been confounded however by the variability in Wnt-Fz interactions.  Nevertheless, 
it has been suggested that proliferation and migration are largely regulated via the two non-
canonical signalling pathways whereas myoblast commitment and differentiation is initiated by 
the canonical, β-catenin dependent pathway (Tanaka et al, 2011; von Maltzahn et al.,2012).  
Research on Wnts in adult tissue is on-going with a great deal of interest being shown in the Wnt 
proteins Wnt3A and Wnt7A which have both been previously linked embryogenesis and more 
recently, myogenesis. 
1.4.7 Wnt3A 
Wnt3A is one of the most widely studied Wnt proteins with numerous publications linking it to 
embryogenesis, more specifically to cell polarization and embryo patterning (Ridgeway et 
al.,2000).  Wnt3A knockout studies carried out in mice have revealed severe deformities and 
abnormalities in developing embryos.  Embryos lacking Wnt3A displayed highly impaired 
cellular patterning and polarization resulting in paraxial mesoderm and laterality defects, loss of 
the tailbud as well as improper vertebral patterning (van Amerongen and Berns, 2007).  Less is 
known however about the role of Wnt3A in adult tissues.  It is believed that Wnt3A plays an 
important role in developmental processes such as myogenesis.  In terms of cell migration, 
exposure to elevated levels of Wnt3A has been seen to reduce the motility of C2C12 
myoblasts(Tanaka et al.,2011) but increase the motility of Chinese hamster ovary cells (Endo et 
al.,2005).  Recently, it has been noted that Wnt3A inhibits the differentiation of mouse C2C12 
cells via the up-regulation of Id3 (inhibitor of differentiation 3) while inducing myofibroblast 
differentiation (into smooth muscle) via the up-regulation of TGF-ß signalling through SMAD2 
in a ß-catenin-dependent manner(Cathy et al.,2011; Zhang et al.,2012).     Furthermore, studies 
carried out on P19 embryonic carcinoma stem cells revealed that Wnt3A promotes myogenesis 
by the up-regulation of MyoD and Myogenin (Ridgeway et al., 2000).  However, injection of 
Wnt3A (10 µl of 100 ng/ml) into regenerating mouse muscle has been shown impair healing 
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(Brack et al., 2008).  These seemingly contradicting findings may be due to differing Fz receptor 
profiles on the different cell types.  Some of the effects of Wnt3A are summarized in table 1.3. 
Table 1.3 The multiple effects of Wnt3A on stem/precursor cells 







Chinese hamster ovary cells (CHO) 
Myofibroblasts 
Tanaka et al.,2011 
Endo et al.,2005 
Cathy et al.,2011 
↑ Rat bone marrow mesenchymal stem cells  Chang et al. 2007 








Myofibroblasts (into smooth muscle) 
Zhang et al.,2012 
Cathy et al.,2011 
↑ P19 embryonic carcenoma stem cells (smooth muscle) Ridgeway et al., 2000 
↑ Rat bone marrow mesenchymal stem cells Chang et al. 2007 
↑ Cardiomyocytes Nakamura et al.,2003 
In addition, in vivo experiments have revealed some important information about Wnt3A.  
Parabiotic studies, linking the circulatory system of old and young mice, have revealed that 
serum factors within the circulatory system of young mice are able to rejuvenate the regenerative 
capacity of satellite cells in skeletal muscle of old mice (Conboy et al. 2005). Conversely 
satellite cells in young mice showed a reduced myogenic differentiation capability and trans-
differentiated to acquire a fibrogenic lineage when exposed to the serum from old mice (Brack et 
al., 2007). This myogenic-to-fibrogenic conversion was reflected by an increased collagen 
deposition further promoting the fibrotic environment. Further analysis revealed the Wnt 
pathway to be a pivotal mediator of the observed, reversible, phenotypic change. Specifically, 
the inhibition of the Wnt pathway by addition of sFRP3 (secreted Frizzled Related Protein 3) to 
the serum from aged mice reduced the myogenic-to-fibrogenic conversion, whereas addition of 
Wnt3A to “young serum” increased this conversion.  It is suspected that the changing Wnt 
expression profile associated with ageing contributed to reduced myogenesis.    
1.4.8 Wnt7A 
Compared to Wnt3A, Wnt7A has been the centre of fewer scientific studies.  It is known 
however that Wnt7A plays an important role in the regulation of cell number.  Wnt7Aover-
expressionin vivo(via the electroporation of a CMV-Wnt7A expression plasmid into mouse leg 
muscle) has been observed to enhance muscle regeneration by increasing both the number and 
proportion of mouse satellite cells in relation to activated myoblasts(Le Grand et al.,2009). 
Muscle lacking Wnt7A exhibited a marked decrease in satellite cell number following 
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regeneration (Le Grand et al.,2009).  This is most likely due to impaired replenishment of the 
quiescent satellite cell pool.  It is suspected that Wnt7A interacts with Fz7, and signals through 
the planar cell polarity pathway to control the homeostatic level of satellite stem cells and hence 
helps regulates the regenerative potential of muscle tissue  (Le Grand et al.,2009; Bentzinger et 
al., 2012; von Maltzahn et al.,2012).  In addition, Wnt7A is able to stimulate the expression of 
the muscle-specific transcription factor, myogenin, in marrow-derived multipotent adult stem 
cell populations (Belema Bedada et al.,2005).  This signalling is thought to be via the planar cell 
polarity pathway and does not affect the growth of myoblasts or their differentiation (Bentzinger 
et al., 2012).  No data is available in terms of the effect of Wnt7A on myoblast migration.  The 
various effects of Wnt7A are summarized below (Table 1.4). 
Table 1.4 The multiple effects of Wnt7A on stem/precursor cells 
Process Effect Cell type Reference 
Proliferation ↑ Mouse skeletal muscle satellite cells Le Grand et al.,2009 
- Myoblasts Bentzinger et al., 2012 
Differentiation - Myoblasts Bentzinger et al., 2012 
 ↑ Marrow-derived multipotent adult stem cells (myogenesis) Belema Bedada et al.,2005 
 
1.5 Myogenic cell lines 
In vitro primary culture myoblasts have successfully been used in research and have provided 
much data relating to myogenesis.  However, using primary culture myoblasts in vitro has a 
number of draw-backs, including the difficulty in isolating pure cultures, the high risk of 
bacterial and fungal contamination during isolation and a limited life-span in culture due to 
senescence.  For this reason, a large portion of research involving myoblast culture makes use of 
‘immortalized’ myogenic cell lines.   One of the most commonly used cell lines in research is the 
mouse C2C12 myoblast line.  The C2 cell line was first cultured from the thigh muscle of C3H 
mice, 3 days after crush injury to the muscle tissue (Yaffe and Saxel, 1977).  Subsequently, the 
C2C12 cell line was produced by sub-cloning of C2 cells, the clone which showed the highest 
degree of differentiation (Blau et al., 1985).  Mutations in the C2C12 myoblast genetic make-up 
allows for prolonged survival in culture and lead to the term ‘immortalized cell line’ (Cornelison, 
2008).  These mutations have not been entirely characterized and are not fully understood.  
C2C12 myoblasts show rapid proliferation and differentiation under culture conditions and have 
a greatly increased lifespan when compared to primary culture.  The myoblasts can be cultured 
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over many passages and can be cryopreserved for use at a later stage.  Despite all these 
advantages, genetic mutations in C2C12 myoblasts result in a cell-line that is not identical to 
primary culture or myoblasts found in vivo.  For this reason, experiments carried out on 
immortalized cell lines such as C2C12 myoblasts should be replicated in primary culture and in 
vivo.     
1.6 Medical importance 
The effective healing and growth of adult skeletal muscle relies heavily on a healthy population 
of correctly functioning satellite cells.  The importance of these satellite cells is evident in people 
or animals with improper cell functionality.  For example, individuals suffering from Duchene 
muscular dystrophy are unable to maintain a healthy population of quiescent satellite cells 
(Vitello et al.,2004, von Maltzahn et al., 2012).  Numerous rounds of degeneration and 
regeneration of muscle tissue in these individuals results in a depletion of satellite cell number.  
This then leads to muscle wasting/dystrophy characterized by the substitution of muscle with 
fatty-fibrous tissue (Vitello et al.,2004).  For this reason, satellite cells and indeed all stem-type 
cells have drawn much interest from the medical world.  Gene therapy involving myogenic 
factors/initiators (such as MyoD and Myf5) as well as direct injection of myoblasts can 
potentially be used to treat animals or people suffering from severe muscle injuries or genetic 
disorders.  In much the same way that people suffering from diabetes require recombinant 
insulin, recombinant myogenic factors and signalling proteins such as Wnts could be used to 
treat muscle diseases such as muscular dystrophy or cystic fibrosis.   
Treatment of diseases via the transplantation of myoblasts or the addition recombinant myogenic 
factors has great potential in terms of wound healing.  However, a number of problems have 
arisen, especially with regards to transplantation of myoblasts.  These difficulties include the 
rejection of the donor myoblasts, decreased migration and wound penetration of the transplanted 
myoblasts and the high expiry rate of injected myoblasts (Guerette et al.,1997).Rejection of 
donor myoblasts is largely due to the once overlooked expression of the major histocompatibility 
complex (MHC) on the cell surface.  This problem can be overcome by injecting an individual’s 
own myoblasts that have been cultured in vivo.  This process requires the harvesting of 
myoblasts from the muscle tissue, expansion of the cell number in vivo and the reinjection of the 
myoblasts.  It is therefore vital to encourage maximum cell proliferation in vivo in order to obtain 
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sufficient myoblasts for transplantation and wound healing.  Potential proliferation-encouraging 
factors such as Wnt7A could be used to increase the yield of transplantable myoblasts.  
Obtaining sufficient numbers of myoblasts to facilitate wound healing via transplantation is one 
of the obstacles for this therapy.  Advances in gene therapy may also be utilized at this time in 
order to correct any detrimental genetic mutations that the myoblasts may have. 
Transplanted myoblasts also show reduced migration; this may be due to the cells becoming 
stuck within the interstitial tissue surrounding the damaged myofibers (Rando et al.,1995).  
Increased integrin-dependent migration of myoblasts could help sufficient cell numbers to reach 
the wound area.  This would need to be accompanied by an increased breakdown of the 
migration-impeding ECM by proteinases such as MMP-2 and MT1-MMP.Treatment of in vivo 
myoblasts with the MMP activating factor, basic fibroblast growth factor (bFGF) prior to 
injection has been shown to increase wound healing (Kinoshita et al., 1995).  This is thought to 
be as a result of increased myoblast motility due to a greater level of ECM breakdown by the 
activated proteinases.   
Another problem with myoblast transplantation is the high level of cell death among the newly 
transplanted cells.  This has been attributed to immune responses following the transplantation.  
One way in which to address this problem is to ensure maximum myoblast proliferation once 
transplanted.  The myoblasts can be treated with specific growth factors prior to injection, 
encouraging increased proliferation once in situ.  The problem with this approach is that most 
proliferation encouraging factors also act to down-regulate differentiation.  This is not ideal as 
this then decreases fusion and thus muscle healing.  Research is therefore on-going to find ways 
to encourage such proliferation without preventing fusion.     
The Wnt family of signalling proteins appear to be highly involved in the process of myogenesis.  
Of particular interest are Wnt3A and Wnt7A which have been shown to affect muscle stem cell 
migration, proliferation and differentiation.  Although some work has been carried out regarding 
Wnt3A and Wnt7A in terms of myogenesis, these studies relied on Wnt-producing cell-lines.  As 
a result of using a Wnt-producing cell-line, the actual concentration of Wnt in the culture 
medium is not always known or stated.  
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The aim of the current study was therefore to analyse the effect of a range of concentrations of 
recombinant Wnt3A and Wnt7A on 1) the proliferation and migration as well as 2) the 























THE EFFECT OF WNT3A AND WNT7A ON PROLIFERATION AND MIGRATION OF 
MOUSE C2C12 AND DONOR-DERIVED HUMAN MYOBLASTS 
______________________________________________________________________________ 
Satellite cells are skeletal muscle stem cells tasked with the growth and repair of muscle 
tissue.  Damage to muscle tissue initiates myogenesis via the activation of satellite cells.  
Activated satellite cells, referred to as myoblasts, migrate to the site of injury where they 
proliferate, differentiate and fuse to repair the tissue.  The speed at which myoblasts 
migrate and proliferate has a major effect on the success of healing.  Diseases such as 
Duchene’s muscular dystrophy are characterised by muscle wasting and the build-up of 
fibrotic tissue as a result of improper maintenance of the satellite cell pool.  The Wnt family 
of secreted proteins are suspected to play an important role in the regulation of cell 
migration and proliferation.  Of particular interest are Wnt3A and Wnt7A which have 
both been linked with myogenesis.   Wnt3A-expressing C2C12 cells have been shown to 
have reduced motility; however treatment with recombinant Wnt3A is known to increase 
migration in Chinese hamster ovary cells and rat-derived fibroblast and mesenchymal stem 
cells in vitro.  Injection of 10µgWnt7Ainto mouse leg muscle appears to increase the 
proportion of quiescent satellite cells.  Previous studies involving Wnts have mostly 
involved an over-expressing cell line and/or Wnt-containing conditioned medium.  In our 
study we wished to evaluate the effect of known concentrations of recombinant Wnt3A and 
Wnt7A on the migration and proliferation of mouse C2C12 and HSkM myoblasts in vitro.  
Using an in vitro wound assay, we established that Wnt3A and Wnt7A at 10 ng/ml and 100 
ng/ml promoted wound closure in injured C2C12 myoblasts at 7 hours post wounding.  
HSkM myoblasts treated with 10 ng/ml Wnt3A also displayed a significant increase in 
motility, confirming the pro-migratory effect of Wnt3A.  Neither Wnt3A nor Wnt7A were 
seen to have any significant effect on C2C12 or HSkM proliferation.  Wnt signalling 








Satellite cells are resident, quiescent skeletal muscle stem cells, characterized by their anatomical 
location between the sarcolemma and myofiber plasma membrane along muscle fibers and by 
their expression of proteins such as Pax7, M-cadherin, c-Met and CD34 (Mauro, 1961; Irintchev 
et al., 1994; Beauchamp et al., 2000; Charge and Rudnicki 2004; Sherwood et al., 2004).  When 
growth or repair of muscle tissue is required, the satellite cells exit quiescence as activated 
myoblasts, migrate to the site of growth/injury, proliferate and then differentiate and fuse to form 
new myotubes or repair damaged muscle (Le Grand and Rudnicki, 2007; Burdzinska et al. 
2008).  This overall process is referred to as myogenesis (Le Grand and Rudnicki, 2007; 
Burdzinska et al. 2008; Griffin et al., 2010).  A proportion of the myoblasts must return to a 
quiescent state in order to maintain the population of satellite cells within the tissue (Le Grand 
and Rudnicki, 2007).  Myoblasts that undergo differentiation and fusion become terminally 
differentiated and are unable to re-enter mitosis (Hawke and Geary, 2001; Le Grand and 
Rudnicki, 2007).  For this reason, a healthy population of satellite cells is required to facilitate 
the healthy growth and repair of muscle tissue.  When an injury has occurred, the success of 
healing is largely determined by the rate at which the activated myoblasts reach the site of injury, 
proliferate and degree to which they differentiate. 
Effective migration of myoblasts is vital for wound healing.  Controlled migration ensures that a 
sufficient number of myoblasts reach the injury site and that the cells are able to line-up and 
form cell-cell adhesions required for differentiation and fusion (Kang et al., 2004; Griffin et al., 
2010).  With every serious injury, the regenerative potential of the muscle tissue is reduced 
(Charge and Rudnicki, 2004).  This is in part due to the deposition of extracellular matrix (ECM) 
factors such as collagen I, resulting in scar tissue as well as the reduction in the number of local 
satellite cells.  Loss of skeletal muscle mass, either due to old age or the recessive, X-linked 
Duchenne muscular dystrophy gene is referred to as sarcopenia and is associated with a 
reduction in satellite cell activity and number (Solomon and Bouloux, 2006).Duchenne muscular 
dystrophy is caused by a mutation in the dystrophin gene.  Dystrophin is an anchor-type protein 
vital for keeping muscle cells intact by tethering structural proteins within the cells to proteins on 
the outer surface of the cell membrane (Sussman, 2002).  The reduced stability of the muscle 
tissue means that wear and tear to the tissue is more severe.  This stimulates excessive satellite 
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cell activation; as a result, the satellite cell population becomes diminished and is unable to cope 
with the rate of tissue damage. 
The Wnt family of secreted proteins consists of 21 highly-conserved, cysteine-rich, lipid-
modified glycoproteins which interact with members the seven-pass transmembrane receptor 
Frizzled (Fz) family (George-Weinstein et al., 1998; Cadigan and Liu, 2006; Maiese et al., 
2008).Wnt proteins may initiate different signalling pathways, depending on both the Wnt type 
and the Fz profile (Cheng et al., 2008).  Signalling may be via the canonical/β-catenin 
dependent, or via one of the two non-canonical pathways, these being; the planar cell polarity 
(PCP) or the Ca2+ dependent pathways (Huelsken and Behrens, 2002; Nusse, 2003; Packard et 
al., 2003; Laeremans et al.,  2010; Tanaka et al., 2011).  It has been suggested that proliferation 
and migration are largely regulated via the two non-canonical signalling pathways whereas 
myoblast commitment and differentiation is initiated by the canonical, β-catenin dependent 
pathway (Tanaka et al, 2011; von Maltzahn et al., 2012). 
Wnt3A is one of the most widely studied Wnt proteins with numerous publications highlighting 
its importance in cell polarization and tissue patterning during embryogenesis (Ridgeway et al., 
2000).  Embryos lacking Wnt3A displayed highly impaired cellular patterning and polarization 
resulting in paraxial mesoderm and laterality defects, loss of the tailbud as well as improper 
vertebral patterning (van Amerongen and Berns, 2007).  In adult tissue, Wnt3A has been shown 
to play an important role in myogenesis.  In vitro studies have shown that Wnt3A-containing 
conditioned medium inhibits the differentiation of C2C12 myoblasts (Cathy et al., 2011; Zhang 
et al., 2012).  This inhibition is thought to be as a result of Wnt3Asignalling via the canonical 
pathway and up-regulating the expression of Id3 (inhibitor of differentiation 3)(Cathy et al., 
2011; Zhang et al., 2012).  It has also been noted that elevated levels of Wnt3A in injured mouse 
muscle leads to impaired muscle repair and an increased deposition of fibrous connective tissue 
(Brack et al.,2007; von Maltzahn et al., 2012).  This impaired healing and build-up of connective 
tissue is typically associated with the regeneration of ‘aged’ muscle.  In terms of cell migration, 
exposure to elevated levels of Wnt3A has been seen to increase the motility of Chinese hamster 
ovary cells as well as rat-derived fibroblast and bone marrow mesenchymal stem cells (Endo et 
al., 2005; Shang et al., 2007, Schlessinger et al., 2009).  It is suspected that Wnt3A is able to 
activate the Rho-associated kinase via the Dishevelled signalling protein which in turn stimulates 
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cell migration through the regulation of actin/myosin contractions (Schlessinger et al., 2009).  
Unexpectedly, over-expression of Wnt3A by C2C12 myoblasts has been seen to reduce 
migration (Tanaka et al., 2011).  This reduced motility may be as a result of constant and 
prolonged exposure to Wnt3A as opposed to an acute and controlled exposure in response to 
injury.  Little research has been conducted in terms of Wnt3A and proliferation.  Studies have 
shown however that Wnt3A-containing conditioned medium increases the proliferation of rat 
bone marrow mesenchymal stem cells via non-canonical signalling (Chang et al., 2007). 
Wnt7A plays an important role in the regulation of cell number.  Injection of Wnt7A has been 
observed to enhance the regeneration of mouse leg muscle by expanding and maintaining the 
satellite cell pool (Le Grand et al., 2009; von Maltzahn et al.,2012).Muscle lacking Wnt7A on 
the other hand exhibited a marked decrease in satellite cell number following regeneration.  This 
is most likely due to impaired replenishment of the quiescent satellite cell pool.  It is suspected 
that Wnt7A interacts with Fz7, and signals through the planar cell polarity pathway to control the 
homeostatic level of satellite stem cells and hence helps regulates the regenerative potential of 
muscle tissue (Le Grand et al., 2009; Bentzinger et al., 2012; von Maltzahn et al., 2012).  No 
published data is available in terms of the effect of Wnt7A on myoblast migration.   
Most Wnt studies have involved an over-expressing cell line which secretes Wnt protein into the 
surrounding medium.  Myoblasts are either maintained in co-culture with the Wnt producing line 
or treated with harvested conditioned media.  Such Wnt-containing conditioned media may 
contain up to a maximum of 200 ng/ml of Wnt (Willert et al., 2003).  In most studies however, 
the concentration of Wnt produced is not mentioned and this makes it difficult to correlate any 
effect to a specific Wnt concentration.  In addition, cells which are grown in co-culture with 
Wnt-producing lines are constantly exposed to the signalling protein.  It is possible that these 
prolonged exposures change the Fz receptor profile; furthermore these conditions do not mimic 
the change in in vivo Wnt expression levels that occur during wound healing.  In the current 
study we analyzed the effect of specific doses of recombinant Wnt3A and Wnt7A on the 





2.2 Materials and Methods 
All chemicals used in the study were of an analytical grade.  Cell culturing was performed under 
sterile conditions in a level II lamina flow hood (ESCO class II BSC).  All cells were incubated 
in an Innova® CO-170 CO2-incubator (New Brunswick) at 37°C, 5% CO2. 
2.2.1 Cell culture 
Cells 
Mouse C2C12, and donor-derived human skeletal muscle (HSkM) myoblasts were used in the 
study.  C2C12 cells are an immortalized myoblast cell line capable of migration, proliferation, 
differentiation and fusion into myotubes.  The C2C12 cells used in the study were kindly donated 
by the Cape Heart Centre, University of Cape Town.  Passages ranged from P12 to P18.  HSkM 
myoblasts were obtained from Lonza (cat.CC-2561, USA) and used at passage P3.   
Culture media 
C2C12 myoblasts were maintained in growth media (GM) consisting of Dulbecco’s Modified 
Eagle’s Medium (with 2% L-glutamine) (Sigma, cat.D5648-1L, USA) supplemented with 10% 
(v/v) fetal bovine serum (Biowest, cat.51810-500, USA), 3.7g/l sodium bicarbonate (Merck, 
cat.103025, USA) and 1% (v/v) Penicillin/Streptomycin (Lonza, cat.DE17-602E, RSA). 
The HSkM cells were cultured in a 50/50 mixture of the C2C12 growth medium (GM) and 
HamsF10 nutrient broth (Sigma-Aldrich, cat.N6908, USA).  This 50/50 media mix was also 
supplemented with 2.5 ng/ml human fibroblast growth factor (hFGF) (Sigma-Aldrich, cat.F0291, 
USA) with the fetal bovine serum concentration adjusted to 20%. 
Thawing and culturing of myoblasts 
Both C2C12 and HSkM cells were received as frozen stocks stored in cryopreservation tubes.  
When required, cells were thawed by gentle heating in a 37°C water bath for 1 minute.  The 
semi-frozen cell suspension was then transferred into a T75 tissue culture flask (Nest Biotech, 
cat.0926B) containing 10 ml of the required medium (GM for C2C12 cells, 50/50 mix for HSkM 
cells).  Exhausted culture medium was replaced with fresh medium every 48 hours during cell 
proliferation within the T75 flasks.  Cells proliferating in the T75 culture flasks were passaged 
before reaching 80% confluence in order to prevent any undesired differentiation.  Cells were 
30 
 
passaged by removing the medium, washing with phosphate buffered saline solution (PBS) and 
incubation with 2 ml trypsin (Cambrex, cat.17-161E) at 37°C for 3 minutes.  After 3 minutes, the 
trypsin activity was neutralized by adding an equal volume of growth medium.  The passaged 
cells were then divided into additional T75 flasks for future use or plated for experimental use. 
2.2.2 Recombinant Wnt proteins 
Recombinant murine Wnt3A (Peprotech, cat.315-20) and recombinant human Wnt7A (R and D 
Systems, cat.3008-WN/CF) were re-suspended in sterile PBS at a concentration of 100 µg/ml.  
At the start of our experimental work, these were the available species of recombinant Wnt3A 
and Wnt7A.  These solutions were stored at -20°C. For both the migration and proliferation 
experiments, C2C12 myoblasts were treated with culture medium containing Wnt at a 
concentration of 0 ng/ml, 1 ng/ml, 10 ng/ml or 100 ng/ml.  Due to the low proliferation rate of 
the HSkM cells, only the Wnt type and dose which showed the greatest effect on the C2C12 cell 
line was tested in human cells. 
2.2.3 Analysis of cell migration in response to Wnt3A and Wnt7A 
Cell migration was analysed using an in vitro wound assay (Goetsch et al., 2011).  A total of 30 
000 cells (C2C12 or HSkM) were plated into the wells of a plastic, 24-well culture dish(TPP, 
cat.Z707791, USA) containing 500µl culture medium per well.  The cells were allowed to reach 
80% confluence after which they were ‘wounded’ using a plastic gel-loading tip.  The culture 
medium was removed and the cells washed with PBS.  Fresh culture medium containing either 
Wnt3A or Wnt7A was then added to the wells.  Photographs of the wound areas were taken at 0, 
3, 5 and 7 hours post-wounding using an Olympus CKX41 microscope(40x magnification) fitted 
with a Moticam 2300 3.0 megapixel camera.  The wound areas of the images were determined 
by tracing along the border of the wound using the Motic2.0 image analysis software.  The 
percentage wound closure at each time point was calculated using the formula:                   
[(wound area at 0 hour - wound area at n hour) ÷ wound area at 0 hour] x 100.  The rates of 
wound closure were calculated by plotting line graphs for the 0-3 hour, 3-5 hour and 5-7 hour 
time periods.  The gradients of these individual line plots were used as the rate of wound closure 





2.2.4 Analysis of cell proliferation in response to Wnt3A and Wnt7A 
Cell proliferation was determined by way of cell counts.  A total of 100 000 (C2C12) or 30 000 
(HSkM) myoblasts were plated into the wells of 6-well plates (Thermo Scientific, catYO-01930-
21, USA) containing growth medium and allowed to settle for 4 hours.  After the cells had 
adhered to the plates, the media was removed and 2 ml of Wnt-containing culture medium 
added.  The myoblasts were incubated for 24 (C2C12) or 48 hours (HSkM), trypsinized and 
counted using a Biorad TC-20 automated cell counter.   
 
2.2.5 Statistical analysis  
All data are represented as mean ± standard error of the mean (SEM) for each data set shown. 
The paired Student’s t-test was performed for parametric data and paired Mann-Whitney U test 
for non-parametric data. All statistical tests were performed using the Genstat 12th edition 
















2.3.1 Wnt3A increases the migration of C2C12 myoblasts 
In order to test the effect of Wnt proteins on migration, C2C12 cells cultured in 24-well plates 
were scratched in order to simulate a wound (Abbi and Guan, 2002; Goetsch et al., 2011).  The 
myoblasts were then treated with Wnt-containing culture media and phase contrast images taken 
at 0, 3, 5 and 7 hours post injury (Figure 2.1). 
 
Figure 2.1 C2C12 myoblast wound areas in response to Wnt3A.  Phase contrast images of wound areas taken at 
0, 3, 5 and 7 hours post wounding.  Wnt3A concentrations are shown on the left.  Yellow borders outline wound 
areas.  40X magnification. 
Calculation of percentage wound closure revealed that Wnt3A (10 ng/ml and 100 ng/ml) 
marginally increased C2C12 myoblast migration over the 7 hour time period (Figure 2.2A).  
Wnt3A at 10 ng/ml significantly increased migration from 18.9% (control) to 22.8% (10 ng/ml) 
after 5 hours of treatment (Figure 2.2C).  After 7 hours, both the 10 ng/ml and 100 ng/mlWnt3A 
treatments had significantly increased migration from 29.1% (control) to 36.3% (10 ng/ml) and 
35.4% (100 ng/ml) (Figure 2.2D).  Unexpectedly, migration was slightly inhibited in response to 
1 ng/mlWnt3A treatment at the 1 hour time point, dropping from 10.2% (control) to 8.9% 










closure (p<0.05) (Figure 2.2B).   Calculation of the rate of wound closure revealed that Wnt3A 
(1 ng/ml) significantly decreased the rate of closure during early wound repair control (p<0.05; 
Figure 2.2E).  However, between 3 and 7 hours, the rate of wound closure was significantly 
increased after treatment with 10 ng/ml Wnt3A (p<0.05, Figure 2.2F and Figure 2.2G). 
 
Figure 2.2 C2C12 myoblast wound repair in response to Wnt3A.  Myoblast migration in response to Wnt3A was 
assessed using an in vitro wound healing assay.  A)The percentage wound closure was determined at 3, 5 and 7 
hours post wounding using the Motic 2.0 image analysis software.  Panels B, C and D show the significant results 
and SEM values for the individual time points that cannot be clearly represented in panel A.  B) Wound closure 3 
hours post-wounding. C) Wound closure 5 hours post-wounding. D) Wound closure 7 hours post-wounding.  E) 
Rate of wound closure, 0-3 hour.  F) Rate of wound closure, 3-5 hour.  G) Rate of wound closure, 5-7 hour.  Data 
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2.3.2 Wnt7A increases the migration of C2C12 myoblasts 
Migration analysis was carried out on C2C12 myoblasts treated with Wnt7A (0, 1, 10, 100 
ng/ml).  Phase contrast images were taken at 0, 3, 5 and 7-hours post wounding (Figure 2.3).  As 
with the Wnt3A treated cells, no obvious differences in wound closure were observed in control 
versus Wnt7A treated cells (Figure 2.2).   
 
Figure 2.3 C2C12 myoblast wound areas in response to Wnt7A.  Phase contrast images of wound areas taken at 
0, 3, 5 and 7 hours post wounding.  Wnt7A concentrations are shown on the left.  Yellow borders outline wound 
areas.  40X magnification. 
Calculation of percentage wound closure revealed that Wnt7A significantly increased wound 
closure at 5 and 7 hours post wounding, but not at the 3 hour time point (Figure 2.2A and Figure 
2.2B).  Wnt7A (10 ng/ml) increased the percentage wound closure from 18.9% to 23.7% at 5 
hours post wounding, a 4.8% increase relative to control (p<0.05; Figure 2.4C).  After 7 hours, 
the higher concentrations were seen to significantly increase migration from 29.1% (control) to 
34.9% (10 ng/ml) and 33% (100 ng/ml) (Figure 2.4D).  The plots for the rates of closure 
mirrored those of total wound closures.  The rates of migration revealed that unlike Wnt3A, 
Wnt7A had no effect on the velocity of migration during early in vitro repair (0-3 hour). 











Figure 2.4 C2C12 myoblast wound repair in response to Wnt7A.  Myoblast migration in response to Wnt7A was 
assessed using an in vitro wound healing assay.  A)  The percentage wound closure was determined at 3, 5 and 7 
hours post wounding using the Motic 2.0 image analysis software.  Panels B, C and D show the significant results 
and SEM values for the individual time points that cannot be clearly represented in panel A.  B) Wound closure 3 
hours post-wounding. C) Wound closure 5 hours post-wounding. D) Wound closure 7 hours post-wounding.  E) 
Rate of wound closure, 0-3 hour.  F) Rate of wound closure, 3-5 hour.  G) Rate of wound closure, 5-7 hour.  Data 
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2.3.3 Wnt3A increases the migration of HSkM myoblasts 
Subsequent to C2C12 migration analysis, HSkM myoblasts were ‘wounded’ and treated with 
Wnt protein.  Due to the difficulty in culturing sufficient numbers of HSkM myoblasts, only the 
Wnt concentration which showed the greatest effect on C2C12 migration was evaluated.  The 10 
ng/mlWnt3A treatment was selected (7.2% increase in wound closure after 7 hours) (p<0.05).  
Phase contrast microscopy images of migrating HSkM cells treated with Wnt3A were captured 
at 0, 3, 5 and 7 hours post-wounding; HSkM myoblasts appeared to close the wound area faster 
than the C2C12 cells (Figure 2.5).   
 
Figure 2.5 HSkM myoblast wound areas in response to 10 ng/ml Wnt3A.  Phase contrast images of wound areas 
taken at 0, 3, 5 and 7 hours post wounding.  Wnt3A concentrations are shown on the left.  Yellow borders outline 
wound areas.  40X magnification. 
Evaluation of the wound areas revealed that Wnt3A significantly increased wound closure in 
HSkM cells at 5 and 7hours but not 3 hours post-wounding(Figure 2.6).  After 5 hours, wound 
closure had increased significantly from 52.9% (control) to 61.1% (10 ng/ml) (p<0.05; Figure 
2.6B).  Incubation with Wnt3A for 7 hours resulted in a significant increase in wound closure 
from 71.6% (control) to 80.9% (10 ng/ml) (p<0.05; Figure 2.6C).  It was also confirmed that the 
HSkM myoblasts were quicker to close the wound area than the C2C12 cell line.  The control 
C2C12 myoblasts reached a total of 29.1% wound closure after 7 hours while the HSkM 
myoblasts reached a figure of 71.6% closure.   Although not significant, it seemed that 
Wnt3Ahad a greater initial effect on HSkM migration when compared to C2C12 cells.  Between 
0-3 hours,10 ng/mlWnt3A increased the rate of HSkM migration from 10.5% (%closure/hour; 
control) to 13.6% (%closure/hour).  After this initial increase, the rate of migration seemed to 
level out at around 10% (%closure/hour) both for the control and Wnt3A treatment.  This was 
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not the case in the C2C12 cells.  In response to Wnt3A, the C2C12 myoblasts appeared to have 
largely unaffected migration during the initial stages of the wound assay (0-3 hours), but 
significantly increased migration during the latter stages (between 3 and 7 hours post wounding). 
 
Figure 2.6 HSkM myoblast wound repair in response to 10 ng/ml Wnt3A.  Myoblast migration in response to 
Wnt3A was assessed using an in vitro wound healing assay.  A)  The percentage wound closure was determined at 
3, 5 and 7 hours post wounding using the Motic 2.0 image analysis software.  Panels B, C and D show the 
significant results and SEM values for the individual time points that cannot be represented in panel A.  B) Wound 
closure 3 hours post-wounding. C) Wound closure 5 hours post-wounding. D) Wound closure 7 hours post-
wounding.  E) Rate of wound closure, 0-3 hour.  F) Rate of wound closure, 3-5 hour.  G) Rate of wound closure, 5-7 




























































B        3 hour C        5 hour D       7 hour





























































2.3.4 Wnt3A has no significant effect on the proliferation of C2C12 myoblasts 
In order to analyse the effect of Wnt3A on myoblast proliferation, 100 000 C2C12 myoblasts 
were seeded in GM into the wells of a 6-well plate and allowed to settle over a 4 hour period. 
The media was removed and Wnt3A-containing media added.  The myoblasts were cultured for 
24-hours and cell counts performed using a Biorad TC-20 automated cell-counter.  It was 
observed that the cells increased in number by 100%.  However, none of the Wnt3A 
concentrations (1 ng/ml, 10 ng/ml and 100 ng/ml) had any significant effect on the proliferation 
of the C2C12 myoblasts (Figure 2.7) 
Figure 2.7 Effect of Wnt3A on C2C12 myoblast proliferation.  The proliferation of C2C12 myoblasts in response 
to Wnt3A was evaluated using cell counts obtained by a Biorad TC-20 automated cell-counter.  A total of 100x103 
C2C12 myoblasts were seeded and treated with Wnt3A at 0 ng/ml, 1 ng/ml, 10 ng/ml or 100 ng/ml for 24 hours.  A) 
Phase contrast images of proliferating cells were taken 24 hours after treatment with Wnt3A.  B)  Cell numbers after 
24 hours were calculated with the initial number of seeded cells represented by the dotted line. Data are expressed as 
mean + SEM; n=4. *p<0.05 (compared to 0 ng/ml). 
2.3.5 Wnt7A has no significant effect on the proliferation of C2C12 myoblasts 
In order to determine the effect of Wnt7A on C2C12 proliferation, myoblasts were incubated 
withWnt7A over a 24-hour period.  The Wnt7A treatments and subsequent cell counts were 
























reduce the increase in cell number when compared to control, this effect was not significant 
(Figure 2.8).   
Figure 2.8 Effect of Wnt7A on C2C12 myoblast proliferation.  The proliferation of C2C12 myoblasts in response 
to Wnt7A was evaluated using cell counts obtained by a Biorad TC-20 automated cell-counter.  A total of 
100x103C2C12 myoblasts were seeded and treated with Wnt7A at 0 ng/ml, 1 ng/ml, 10 ng/ml or 100 ng/ml for 24 
hours.  A) Phase contrast images of proliferating cells were taken 24 hours after treatment with Wnt7A.  B)  Cell 
numbers after 24 hours were calculated with the initial number of seeded cells represented by the dotted line. Data 
are expressed as mean + SEM; n=4. *p<0.05 (compared to 0 ng/ml). 
 
2.3.6 Wnt7A has no effect on the proliferation of HSkM myoblasts 
Although not significant, it appeared that Wnt7A at the 10 ng/ml and 100 ng/ml concentrations 
had a slightly inhibitory effect on C2C12 myoblast proliferation.  In addition, Wnt7A has 
previously been linked to the regulation of satellite cell quiescence (Le Grand et al., 2009; 
Bentzinger et al., 2012; von Maltzahn et al., 2012).  As a result, we decided to investigate 
whether 100 ng/ml Wnt7A affects HSkM myoblast proliferation.  A total of 30 000 HSkM 
myoblasts were plated into the wells of a 6-well plate, allowed to settle and subsequently treated 
with Wnt7A-containing GM.    Due to their relatively slow doubling time, the HSkM cells were 
incubated for 48 hours before cell counts were performed.  Analysis of the HSkM cell numbers 
























Figure 2.9 Effect of 100 ng/ml Wnt7A on HSkM myoblast proliferation. The proliferation of HSkM myoblasts 
in response to Wnt7A was evaluated using cell counts obtained by a Biorad TC-20 automated cell-counter.  A total 
of 30x103HSkM myoblasts were seeded and treated with Wnt7A at 0 ng/ml or 100 ng/ml for 48 hours. A) Phase 
contrast images of proliferating cells were taken 48 hours after treatment with Wnt7A.  B) Cell numbers after 48 
hours were calculated with the initial number of seeded cells represented by the dotted line. Data are expressed as 




































The Wnt family of secreted, signalling proteins are known to regulate embryonic patterning and 
tissue development.  In addition to embryogenesis, the Wnt proteins are involved in adult tissue 
development.  It is thought that Wnts help regulate the migration and proliferation of tissue 
progenitor cells during processes such as myogenesis.  The rate at which muscle progenitor cells 
reach the site of injury and the degree to which they proliferate can greatly affect the success of 
healing.  In this study, we attempted to define the in vitro effects of Wnt3A and Wnt7A on both 
the migration and proliferation of mouse and human skeletal muscle myoblasts.       
The migration of myoblast cells was evaluated using an in vitro wound healing assay.  Myoblasts 
were cultured until 80% confluent, wounded and treated with Wnt-containing growth medium.  
Phase contrast microscopy images were taken over a 7 hour period and the percentage wound 
closure calculated.  The results of these treatments are summarized in Table 2.1. 
Table 2.1 Effect of Wnt3A and Wnt7A on C2C12 migration (n=6, *p<0.05) 
Wnt 
Concentration(ng/ml) 
Total Wound Closure (% closure) 
Wnt3A 3 hour treatment 5 hour treatment 7 hour treatment 
0 10.2 18.9 29.1 
1 8.93* 20.0 30.2 
10 10.8 22.7* 36.3* 
100 11.5 21.3 35.4* 
 
Wnt7A 
   
0 10.2 18.9 29.1 
1 11.2 21.1 32.8 
10 11.3 23.7* 34.9* 
100 12.2 21.9 33.0* 
Surprisingly, Wnt3A at 1 ng/ml had a slight but significant (p<0.05) inhibitory effect on C2C12 
migration at the 3 hour time point.Wnt3A at 10 ng/ml and 100 ng/ml significantly increased the 
rate of C2C12 myoblast migration after 5-7 hours of treatment (p<0.05).  It is possible that a 
cell’s response to Wnt is dependent on both the concentration of the signalling molecule and the 
length of exposure.  The increase in motility at the higher Wnt3A concentrations seems to 
contradict the study conducted by Tanaka et al (2011).  Using an expression plasmid, Tanaka 
and his associates produced a line of Wnt3A over-expressing C2C12 myoblasts (Wnt3A-
C2C12).  These cells displayed reduced motility in a 2D wound assay (after 16 hours).  Motility 
was equated to the number of cells that had moved into a 2D wound area during the assay.  The 
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contradiction of results is not fully understood and may have a number of reasons.  Firstly, 
Tanaka et al (2011) made use of a 16-hour 2D wound assay.  Since the doubling time of 
myoblasts is regularly around 12-14 hours, wound closure due to cell proliferation may have 
occurred.  A 7-hour 2D wound assay was utilized in our study in order to minimize undesired 
proliferation.  The high flexibility of Wnt-Fz interactions may be a possible cause of the 
contradicting results.  Different receptor profiles on the two populations of C2C12 cells would 
result in two different signalling pathways being activated.  mRNA analysis of Wnt, Fz and 
LRP5/6 expression is required for a more complete overview of the signalling pathways. 
In the study carried out by Tanaka et al (2011), Wnt3A-producing C2C12 cells were cultured in 
medium for 48 hours before wounding.  Since Wnt production is heavily reliant on the presence 
of certain serum factors, it is conceivable that during the 48 hour incubation, some of these 
factors would have been depleted (Chakkalakal and Brack, 2012).  Serum factors required for 
migration may have been among those depleted leading to the decrease in migration. It has been 
observed that a number of serum factors are able to bind to Fz and can affect the level of Wnt 
signalling (Chakkalakal and Brack, 2012).  For example, the complement C1q, which is found in 
elevated levels in “aged” serum, has recently been shown to bind to Fz and encourages canonical 
Wnt signalling in satellite cells (Naito et al., 2012).  Therefore, serum factors could directly and 
indirectly affect Wnt signalling. The C2C12 myoblasts used by Tanaka et al (2011) over-
expressed Wnt3A; it is possible that the prolonged exposure to Wnt3A altered the Fz receptor 
profile of the myoblasts or activated alternate signalling pathways.  There is little support for this 
however as Mukai et al. (2010) found no evidence that extracellular Wnt levels influence Fz 
ubiquitylation–deubiquitylation in Hela cells.  No publications could be found regarding adult 
skeletal myoblasts and their Fz receptor profiles in response to Wnt.  Finally, the concentration 
of Wnt3A secreted by the C2C12 myoblasts was not stated in the study by Tanaka et al (2011).  
This again makes it difficult to directly compare these findings to our own.  It is possible that 
Wnt3Aacts in a strictly dose-dependent manner, inhibiting migration at low concentrations and 
enhancing it at higher concentrations.  This may explain the observed inhibition of migration by 
1 ng/mlWnt3A (after 3 hours) and the increased migration caused by the 10 ng/ml and 100 ng/ml 
concentrations (at 5 and 7 hours post wounding).  If the Wnt3A-C2C12 myoblasts produced 
relatively low levels of Wnt3A, this may explain the reduced migration.  This seems unlikely 
however as Wnt producing cell lines typically produce larger amounts of protein. For example, 
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conditioned medium produced by the commonly usedLWnt3Afibroblast line (mouse-derived) 
typically contains between 100 ng/ml and 200 ng/ml of Wnt3A (Willert et al., 2003).   
Exposure to Wnt7A was seen to significantly increase the migration of C2C12 myoblasts at both 
10 ng/ml and 100 ng/ml.  Wnt7A has previously been shown to activate the planar cell polarity 
pathway (PCP) in satellite cells via the Fz7 receptor (Le Grand et al., 2009).  The PCP pathway 
results in cytoskeletal re-organization and the coordinated polarization of cells, which is required 
for migration (Cadigan and Nusse, 1997; Huelsken and Behrens, 2002; Cadigan et al., 2005).  It 
is conceivable that Wnt7A, signalling via the PCP pathway, results in cell polarization and 
cytoskeletal reorganization, thus increasing the migration of C2C12 myoblasts.   In our research, 
we were unable to find any previous publications regarding Wnt7A and myoblast migration; this 
suggests that our findings may be novel. 
The greatest effect on C2C12 migration was stimulated by 10 ng/mlWnt3A, 7 hours post injury.  
For this reason, the 10 ng/mlWnt3A concentration was chosen for the HSkM myoblast wound 
assay.  Our data indicated that between the 3 and 7 hour time points, there was a significant 
increase in HSkM migration in response to Wnt3A.  The calculated wound closures are 
summarized in Table 2.2. 
Table 2.2 Effect of Wnt3A on HSkM migration 
Wnt3A Concentration 
(ng/ml) 
Total Wound Closure (% closure, n=4,  *p<0.05) 
 3 hour treatment 5 hour treatment 7 hour treatment 
0 31.5 52.9 71.6 
10 40.5 61.1* 80.9* 
By comparing the values in Tables 2.1 and 2.2, it is apparent that the HSkM myoblast wound 
closure values are substantially larger than those than those for the C2C12 cell line.  The 
variance in wound closure is most likely due to the different donor species (mouse vs. human) as 
well as inherent differences between primary culture and an immortalized cell line.  Despite this, 
it is obvious that Wnt3A increases the rate of wound closure for both cell types.  This was 
suspected as Wnt proteins show a high level of interspecies relatedness.  A BLAST alignment of 
mouse and human Wnt3A revealed a 97% sequence identity (Appendix II) and although 
recombinant mouse Wnt3A was used in this study, the high level of sequence identity suggests 
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that using human Wnt3A would likely yield the same results.   Once again, our findings appear 
to be novel as no previous studies could be found regarding Wnt3A and HSkM migration.   
Proliferation of C2C12 cells in response to Wnt protein was evaluated by culturing myoblasts in 
Wnt-containing medium for 24 hours, followed by analysis of cell numbers.  The resulting cell 
counts revealed that neither Wnt3A nor Wnt7A had any significant effect on the proliferation of 
C2C12 myoblasts.  This lack of an effect was unexpected as both Wnt3A and Wnt7A have been 
previously linked with the regulation of cell numbers.  Wnt3A is known to increase the 
proliferation of rat bone marrow mesenchymal stem cells in vitro (Chang et al., 2007).  Wnt7A 
on the other hand has previously been shown to encourage the expansion of the satellite cell pool 
in vivo (Le Grand et al., 2009, von Maltzahn et al., 2012).  In our study, C2C12 myoblasts 
cultured in vitro were treated with GM containing recombinant Wnt7A.  It is possible that serum 
and extracellular matrix factors present in vivo cause Wnt7A to signal via a different pathway 
when compared to Wnt7Ain vitro.  A study by Bentzinger et al. (2013) found that it is Wnt7A in 
conjunction with fibronectin that regulates cell number.  The Frizzled receptor Fz7 and the 
membrane bound Syndecan-4 protein were seen to form a co-receptor complex that binds to 
fibronectin and stimulate the ability of Wnt7A to expand the satellite cell pool (Bentzinger et al., 
2013). Since fibronectin was not present in our in vitro study, this may be why the in vivo and in 
vitro results differ.  The relationship between fibronectin, Wnt7A and myoblast proliferation was 
only noted after completion of our experimental work.  In future work we intend to include 
proliferation studies involving Wnt7A and myoblasts grown on ECM factors such as fibronectin. 
To determine the effect of Wnts on human myoblast proliferation,Wnt7A was selected as it has 
previously been shown to be important in terms of satellite cell pool maintenance.  HSkM 
myoblasts treated with 100 ng/ml recombinantWnt7A did not show any significant change in cell 
number when compared to the control.  This result was not entirely unexpected as Wnt7A had no 
significant effect on C2C12 cell number.  BLAST analysis of human and mouse Wnt7A revealed 
a 99% sequence identity (Appendix II). 
In conclusion, it would seem that any results pertaining to Wnt signalling are highly dependent 
on conditions such concentration, serum factors, the cell’s Fz profiles and potentially ECM 
factors.   In our study, C2C12 and HSkM cells cultured in monolayer and treated with 
recombinant Wnt3A generally showed an increase in mobility.  This was evident at 10 ng/ml and 
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100 ng/mlWnt3A.  However, Wnt3A appeared to have no significant effect on the proliferation 
of either C2C12 or HSkM myoblasts.  Although Wnt3A at higher doses was seen to increase the 
level of both C2C12 and HSkM migration, its use in regenerative therapy may be limited as 
injection of Wnt3A into injured mouse muscle has been shown to inhibit myogenesis (Brack et 
al., 2008).  This reduced healing however has been attributed to an inhibition of differentiation 
and it is therefore possible that at the right concentration, injected Wnt3A could increase the 
number myoblasts to reach the site of injury prior to differentiation.Wnt7A was also shown to 
increase migration at both 10 and 100 ng/ml.  This result appears to be novel.  Wnt7A however 
had no effect on proliferation.  This was unexpected as Wnt7A has been shown to increase 
proliferation in the presence of fibronectin (Bentzinger et al.,2013).  Future migration and 
proliferation work will include the culturing of myoblasts on various ECM factors in the present 
of Wnt protein.  It is apparent that our study is one of the first to determine the dose dependent 
















THE EFFECT OF WNT3A AND WNT7A ON THE DIFFERENTIATION OF MOUSE 
C2C12 AND HUMAN PRIMARY CULTURE MYOBLASTS 
____________________________________________________________________________ 
Activated skeletal muscle stem cells, known as myoblasts, facilitate the growth and repair 
of muscle tissue.  These satellite cells are activated by injury to the muscle tissue after 
which they move to the site of damage and initiate repair.  The degree to which these stem 
cells are able to differentiate and fuse to form myotubes has great bearing on the success of 
healing.  The process of differentiation is heavily controlled by a group of helix-loop-helix 
transcription factors known as the myogenic regulatory factors (MRFs).  This group 
includes MyoD, Myf5, myogenin and Mrf4.  It is suspected that these myogenic regulatory 
factors, and indeed the entire process of myogenesis, are in part controlled by the activity 
of the Wnt family of secreted signalling proteins.  The Wnt family is made up of 21 highly 
conserved, cysteine rich signalling molecules which are known to regulate tissue 
development.  Classically, Wnt proteins have been linked with embryogenesis, but recently 
a number have been shown to play a role adult tissue development and maintenance.  
Wnt3A-expressing C2C12 myoblasts have been previously shown to display reduced 
differentiation.  It is suspected that this inhibition is caused by an up-regulation of the 
inhibitor of differentiation 3 (Id3).  No research publications were found regarding the 
effect of Wnt7A on myoblast differentiation; however Wnt7A has been heavily linked with 
maintenance of the satellite cell pool and could possible regulate the production of 
myotubes in a direct manner.  In the current study we aimed to test the effect of known 
concentrations of recombinant Wnt3A and Wnt7A on the differentiation of mouse C2C12 
and donor-derived human skeletal muscle (HSkM) myoblasts in vitro. Expression of the 
contractile muscle protein, myosin heavy chain (MyHC), was used to measure terminal 
differentiation.  Only Wnt3A had a detrimental effect on C2C12 differentiation.  Wnt7A 
appeared to have a minimal effect, possibly increasing differentiation slightly.  Nuclear 
MyoD levels were analysed using confocal microscopy in order to determine the level of 
commitment to differentiation.  Wnt3A (10 ng/ml and 100 ng/ml) was seen to reduce the 





Injury or trauma to skeletal muscle tissue results in the activation of resident, quiescent stem 
cells known as satellite cells (Beauchamp et al., 2000; Charge and Rudnicki 2004; Sherwood et 
al.,2004).  Activated satellite cells, referred to as myoblasts, migrate to the site of injury where 
they proliferate, differentiate, and finally fuse to form new fibers to repair damaged muscle (Le 
Grand and Rudnicki, 2007; Burdzinska et al. 2008). The terminal differentiation of these 
myoblasts is required for fusion so that repair of fibers can take place; it is therefore apparent 
that the success of healing post-injury is directly affected by the degree of differentiation.  The 
differentiation of skeletal muscle myoblasts is a highly controlled, three step process which 
involves; a) the expression of muscle-specific regulatory factors, b) exit from the cell cycle and 
c) expression of contractile muscle proteins (Moran et al.,2002). 
During the initial step of differentiation, there is an up-regulation of the four myogenic 
regulatory factors (MRFs).  These muscle specific regulatory factors are MyoD, myogenin, Mrf4 
and Myf5 (Moran et al., 2002).The second step of differentiation is characterized by the 
irreversible withdrawal of myoblasts from the cell cycle (Moran et al.,2002; Joulia et al, 
2003).Gene knockout experiments carried out in mice suggest that MyoD initiates myoblast 
lineage commitment by the up-regulation of myogenin and Mrf4 (Le Grand and Rudnicki, 2007, 
Ustanina et al., 2007).   Studies have also revealed a degree of functional redundancy between 
Myf5 and MyoD.  Mice lacking a functional MyoD gene have no physical abnormalities, but 
express four-fold higher levels of Myf5 (Megeney et al.,1996).  Similarly mice lacking a 
functional Myf5 gene show a four-fold increase in MyoD expression and no physical 
abnormalities (Megeney et al.,1996).  Although primary involved with proliferation, it is 
suspected that Myf5 is able to compensate in part for the absence of MyoD.  Despite this 
compensation, the rate of differentiation of MyoD knockout myoblasts is decreased.  MyoD is 
therefore commonly used as a marker of myoblast commitment.  Following up-regulation of 
MyoD and Myf5 expression, increased levels of myogenin and Mrf4 initiate the third step of 
differentiation, which involves terminal differentiation and fusion into myofibers (Charge and 
Rudnicki, 2004).  During this third step, contractile motor proteins such as myosin are produced 
(Weiss and Leinwand, 1996; Maccatrozzo et al.,2007).  Myosins consist of smaller subunits 
which include the quintessential muscle marker, myosin heavy chain (MyHC) (Maccatrozzo et 
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al.,2007).  It is the myosin heavy chain (MyHC) subunits that give myosin its contractile and 
filament-forming abilities (Weiss and Leinwand, 1996; Quintin et al., 2008).  Terminally 
differentiated myoblasts fuse to form multi-nucleated myotubes (Weiss and Leinwand, 1996; 
Moran et al., 2002; Maccatrozzo et al.,2007).  It has recently been determined that the MRFs 
involved during myogenesis are regulated by the signalling of the Wnt family of secreted 
proteins (Brack et al.,2008; Bentzinger et al., 2012). 
Wnt signalling proteins are a family of highly, conserved, cysteine-rich and lipid-modified 
glycoproteins (George-Weinstein et al.,1998; Cadigan and Liu, 2006; Maiese et al., 2008).Wnt 
signalling involves the binding of extracellular Wnt to the receptor Frizzled (Fz) and leads to the 
activation of Wnt target genes (Peifer and Polakis, 2000; Huelsken and Behrens, 2002; Janda et 
al., 2012).It is thought that myoblast commitment and differentiation is initiated by the β-catenin 
dependent Wnt signalling pathway (Tanaka et al, 2011; von Maltzahn et al.,2012).  In light of 
these findings, much attention had been placed on Wnt signalling during muscle growth and 
healing.   
Wnt3A is one of the most widely studied Wnt proteins with a number of publications outlining 
its importance during embryogenesis.  Wnt3A knockout studies carried out in mice have resulted 
in severely deformed embryos with highly impaired cellular patterning and polarization resulting 
in defects to the paraxial mesoderm, loss of the tailbud and incorrect vertebral patterning (van 
Amerongen and Berns, 2007).  Wnt3A has also been observed to have an effect of adult tissue 
cells.  In vitro studies suggest that Wnt3A-conditioned medium reduces the level on terminal 
differentiation of C2C12 myoblasts (Cathy et al.,2011; Zhang et al.,2012).  It is suspected that 
Wnt3A, signalling via the β-catenin dependent pathway, up-regulates the expression of the 
inhibitor of differentiation 3 (Id3) and results in reduced differentiation (Cathy et al.,2011; 
Zhang et al.,2012).  Inhibitors of differentiation are a family of regulatory proteins which contain 
a helix-loop-helix (HLH) domain but lack a basic domain (Liu et al.,2002; Pammer et al.,2004).  
These proteins form non-functional heterodimers with basic helix-loop-helix (bHLH) 
transcription factors such as MyoD and myogenin, preventing DNA binding and inhibiting 
differentiation (Liu et al.,2002).  Over-expression of the Id proteins Id1, Id2 and Id3 have been 
shown to result in decreased differentiation in a number of cell types (Langlands et al., 1997; Liu 
et al., 2002).  Reduced healing has been reported in injured mouse leg muscle tissue in 
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whichWnt3A is overexpressed (via the electroporation of a CMV-Wnt7A 
expression plasmid into mouse leg muscle) (von Maltzahn et al. 2012).  However, the conclusion 
reached by von Malzahn et al(2012) was that Wnt3A promotes premature myoblast 
differentiation via canonical signalling, leading to a depletion of the satellite cell pool and 
impaired healing.  It is also possible that the impaired healing was due to inhibited differentiation 
rather than premature differentiation as suggested by Zhang et al. (2012).  Furthermore, 
excessWnt3A at the site of injury lead to an increased deposition of fibrous connective tissue 
(largely collagen), which is an unfavourable effect typically associated with the regeneration of 
‘aged’ muscle (von Maltzahn et al., 2012).  It is apparent that further research into Wnt3A is 
required to fully understand its role during myogenesis and mechanism of action. 
In vivo studies carried out in mice have shown that over-expression of Wnt7A enhances muscle 
regeneration, increasing both the number and proportion of satellite cells relative to activated 
myoblasts (Le Grand et al.,2009; von Maltzahn et al.,2012).  Wnt7A has been shown to interact 
with the Fz7 receptor, activating the planar cell polarity pathway (PCP) and thereby control 
satellite cell number (Le Grand et al.,2009; Bentzinger et al., 2012; von Maltzahn et al.,2012).  
In addition to maintaining the satellite cell pool, Wnt7A has been shown to increase myotube 
size and weight in vivo.  A study in which of Wnt7A (10μg) was injected into injured mouse leg 
muscle resulted in thicker and heavier muscle (25% increased wet eight) with a 1.2 fold greater 
contractile force relative to untreated muscle (von Maltzahn et al.,2012).  In addition, exposure 
to elevated levels of Wnt7A stimulates the expression of the muscle-specific transcription factor, 
myogenin, in marrow-derived multipotent adult stem cell populations (Belema Bedada et 
al.,2005).  It is therefore conceivable that Wnt7A may increase the differentiation of skeletal 
muscle myoblasts via the up-regulation of myogenin.   
In most published in vitro studies, cells have been exposed to Wnt-containing conditioned 
medium.  Conditioned medium may contain varying concentrations of Wnt protein depending on 
the serum factors present, the Wnt type and the cell line producing the protein.  For this reason it 
is often difficult to correlate observed effects to specific Wnt concentration.  In addition, Wnt 
expressing cell lines will produce a number of non-Wnt proteins that may affect any response to 
the produced Wnt.  For example, 3T3 fibroblasts are commonly used to produce Wnt protein.  
However, these cells will also secrete factors such as fibroblast growth factor (FGF) and ECM 
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factors such as fibronectin which could potentially alter Wnt signalling.  In the current study we 
analyzed the effect of specific concentrations of recombinant Wnt3A and Wnt7A on the 






















3.2 Materials and Methods 
All chemicals used in the study were of an analytical grade.  Cell culturing was performed under 
sterile conditions in a level II lamina flow hood (ESCO class II BSC).  All cells were incubated 
in an Innova® CO-170 CO2-incubator (New Brunswick) at 37°C, 5% CO2. 
3.2.1 Cell culture 
Cells 
Mouse C2C12, and donor-derived human skeletal muscle (HSkM) myoblasts were used in the 
study.  C2C12 cells are an immortalized myoblast cell line capable of migration, proliferation, 
differentiation and fusion into myotubes.  The C2C12 cells used in the study were kindly donated 
by the Cape Heart Centre, University of Cape Town.  Passages ranged from P12 to P18.  HSkM 
myoblasts were obtained from Lonza (cat.CC-2561, USA) and used at passage P3.   
Culture media 
C2C12 myoblasts were maintained in growth media (GM) consisting of Dulbecco’s Modified 
Eagle’s Medium (with 2% L-glutamine) (Sigma, cat.D5648-1L, USA) supplemented with 10% 
(v/v) fetal bovine serum (Biowest, cat.51810-500, USA), 3.7g/l sodium bicarbonate (Merck, 
cat.103025, USA) and 1% (v/v) Penicillin/Streptomycin (Lonza, cat.DE17-602E, RSA). 
The HSkM cells were cultured in a 50/50 mixture of the C2C12 growth medium (GM) and 
HamsF10 nutrient broth (Sigma-Aldrich, cat.N6908, USA).  This 50/50 media mix was also 
supplemented with 2.5 ng/ml human fibroblast growth factor (hFGF) (Sigma-Aldrich, cat.F0291, 
USA) with the fetal bovine serum concentration adjusted to 20%. 
Thawing and culturing of myoblasts 
Both C2C12 and HSkM cells were received as frozen stocks stored in cryopreservation tubes.  
When required, cells were thawed by gentle heating in a 37°C water bath for 1 minute.  The 
semi-frozen cell suspension was then transferred into a T75 tissue culture flask (Nest Biotech, 
cat.0926B) containing 10 ml of the required medium (GM for C2C12 cells, 50/50 mix for HSkM 
cells).  Exhausted culture medium was replaced with fresh medium every 48 hours during cell 
proliferation within the T75 flasks.  Cells proliferating in the T75 culture flasks were passaged 
before reaching 80% confluence in order to prevent any undesired differentiation.  Cells were 
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passaged by removing the medium, washing with phosphate buffered saline solution (PBS) and 
incubation with 2 ml trypsin (Cambrex, cat.17-161E) at 37°C for 3 minutes.  After 3 minutes, the 
trypsin activity was neutralized by adding an equal volume of growth medium.  The passaged 
cells were then divided into additional T75 flasks for future use or plated for experimental use. 
3.2.2 Recombinant Wnt proteins 
Recombinant murine Wnt3A (Peprotech, cat.315-20) and recombinant human Wnt7A (R and D 
Systems, cat.3008-WN/CF) were re-suspended in sterile PBS at a concentration of 100 µg/ml.  
At the start of our experimental work, these were the available species of recombinant Wnt3A 
and Wnt7A.  These solutions were stored at -20°C. For both the migration and proliferation 
experiments, C2C12 myoblasts were treated with culture medium containing Wnt at a 
concentration of 0 ng/ml, 1 ng/ml, 10 ng/ml or 100 ng/ml.  Due to the low proliferation rate of 
the HSkM cells, only the Wnt type and dose which showed the greatest effect on the C2C12 cell 
line was tested in human cells. 
3.2.3Analysis of MyoD positive nuclei 
Sterile glass coverslips were placed into the wells of a plastic 24-well culture plate (TPP, cat. 
Z707791, USA).  A total of 30 000 C2C12 or HSkM myoblasts in 500 µl growth medium (GM) 
were plated onto each coverslip.  Myoblasts were cultured to 80% confluence before the GM was 
removed and replaced with Wnt-containing differentiation medium (DM).  C2C12 myoblasts 
were cultured in differentiation medium (DM) containing either Wnt3A or Wnt7A at a 
concentration of 0 ng/ml, 1 ng/ml, 10 ng/ml or 100 ng/ml.  HSkM myoblasts can only be used 
until passage 4, after which time they senesce.  Due to this limitation, only the Wnt treatment 
which showed the greatest effect on C2C12 myoblasts was used.  Confocal microscopy was used 
to determine the percentage of MyoD positive nuclei after 24 or 72 hours incubation with Wnt.  
After incubation with Wnt, the myoblasts were washed with phosphate buffered saline (PBS) and 
fixed with 4% paraformaldehyde for 20 minutes.  Following fixing, the cells were washed with 
PBS and blocked using 5% donkey serum for 1 hour.  The myoblasts were then incubated with a 
rabbit polyclonal anti-MyoD primary antibody (1/100, Santa Cruz, cat. sc-760, USA) for 2 hours 
at room temperature.  Coverslips were then washed with PBS (4 x 5 minutes washes) and 
incubated with a fluorophore-linked donkey anti-rabbit IgY secondary antibody (1/1000, Abcam, 
cat.ab96919, UK) for 1 hour at room temperature.  The myoblasts were then washed with PBS (2 
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x 5 minutes) and treated with 10 µg/ml Hoechst 33342 nuclear stain (Sigma-Aldrich; USA) for 5 
minutes.  The cells were again washed with PBS (3 x 5 minutes) and mounted on glass slides 
using moviol.  Labelled myoblasts were viewed using a Zeiss LSM 710 confocal microscope.  
For each Wnt concentration, a total of 5 fields of view containing at least 20 cells were analysed.  
This was repeated for each experiment (n = 4).  The percentage MyoD positive nuclei were 
calculated using the formula: 100 x (MyoD positive nuclei/total nuclei). 
 
3.2.4 Analysis of morphology  
The morphology of differentiating myoblasts treated with Wnt protein was analysed using both 
phase contrast and confocal microscopy.   C2C12 and HSkM myoblasts were cultured to 80% 
confluence on glass coverslips in 24-well plates and subsequently treated with Wnt-containing 
differentiation medium for a total of 5 days.  Exhausted differentiation medium was removed 
after 72 hours and fresh Wnt-containing medium added.  Phase contrast images were taken using 
an Olympus CKX41 microscope fitted with a Moticam 2300 3.0 megapixel camera (40x 
magnification).  After 5 days of differentiation, the myoblasts were fixed using 4% 
paraformaldehyde (20 minutes), washed with PBS (2 x 5 minutes) and blocked using 5% donkey 
serum (1 hour).The myoblasts’ actin cytoskeletal structures were then labelled by treating with 
phalloidin (fluorophore linked) for 1 hour at room temperature.  The cells were then washed with 
PBS (2 x 5 minutes), treated with 10 µg/ml Hoechst 33342 nuclear stain (5 minutes).  The 
coverslips underwent a final PBS wash (2 x 5 minutes) and were mounted on glass slides using 
moviol.  The labelled myoblasts were viewed using a Zeiss LSM 710 confocal microscope. 
 
3.2.5 Analysis of MyHC expression 
SDS-PAGE 
Protein lysates were prepared according to Appendix IV.  SDS-PAGE was carried out following 
the Laemmli protocol (Laemmli, 1970) and is outlined in Appendix IV.  All gels were run in a 
bench-top electrophoresis unit (Biorad: Mini-PROTEIN 3 Cell, USA) and consisted of a 4.5% 
stacking and 12.5% running gels.  A total of 20 µg protein lysate was typically added to each of 
the wells.  Before loading, lysates were mixed with an equal volume of reducing sample 
treatment buffer as well as 1µl of bromophenol blue (Saarchem, cat.1437500CB, RSA) and 
boiled for 90 seconds.  The PeqGold protein marker V (Peqlab, cat27-2210, Germany) was used 
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to determine protein band size.  Once run, gels were either prepared for Western blotting or 
stained with the Coomassie G-250.    
 
Western blotting 
Western blotting was carried out according to the protocol outlined in Appendix V.  SDS-PAGE 
proteins were transferred to nitrocellulose membranes (Hybond-C Extra; Amersham Biosciences, 
UK) using a standard bench-top Western blotting apparatus (Omni Page, Cleaver Scientific Ltd, 
UK).  Blots were transferred at 100 mA for 16 hours at 4 °C.  Ponceau S. staining was used to 
determine protein transferral to the nitrocellulose membrane.  Membranes were blocked using 
5% milk powder and treated with primary and HRPO-linked secondary antibodies as outlined in 
Appendix V.  Antibody dilutions are outlined in Appendix III.   
 
3.2.5 Statistical analysis  
All data are represented as Mean ± standard error of the means (SEM) for each data set shown. 
The paired Student’s t-test was performed for parametric data and paired Mann-Whitney U test 















3.3.1 Wnt3A inhibits terminal differentiation of C2C12 myoblasts 
C2C12 myoblasts were cultured on glass coverslips in 6-well plates until 80% confluence was reached.  
GM was then discarded, the cells washed with PBS and DM containing Wnt3A (0 ng/ml, 1 ng/ml, 10 
ng/ml or 100 ng/ml) added.  The myoblasts were differentiated for a total of 5 days with media (including 
Wnt3A) being replaced every 72 hours.  Although neither the half-life of Wnt3A or Wnt7A are published, 
these proteins are highly stable due to their glycosylated nature (Sola and Griebenow, 2010). Replacement 
of Wnts was therefore synchronised with media changes.  Phase contrast microscopy revealed that an 
increase in Wnt3A concentration resulted in a decrease in the number of myotubes formed (Figure 3.1A).  
Myotube formation was also visualized by labelling the actin cytoskeleton with Phalliodin.  Fewer 
myotubes expressing actin were seen in the Wnt3A treated monolayers (Figure 3.1B).  The total 
expression of myosin heavy chain (MyHC) was also evaluated in response to Wnt3A (Figure 3.1C).  
Wnt3A decreased MyHC expression in a dose-dependent manner.  Relative to the control, the 1 ng/ml, 10 
ng/ml and 100 ng/mlWnt3A treatments resulted in a 39%, 88% and 94% decrease in MyHC levels 
respectively (Figure 3.1D). 
Figure 3.1 Differentiation of C2C12 myoblasts in response to Wnt3A.  A) Phase contrast images of differentiating myoblasts 
were taken after 5 days incubation with Wnt3A at 0 ng/ml, 1 ng/ml, 10 ng/ml or 100 ng/ml.  B) The actin cytoskeletal structure 
was labelled with phalloidin (green) and the myonuclei with Hoechst (blue). C) Western blots to determine MyHC expression 
were carried out on lysates prepared from day 5 differentiated myoblasts.  Alpha-tubulin was used as the internal loading control. 
D) Densitometry was performed on the blots using the ImageJ, image analysis software and MyHC levels relative to alpha-




























0                      1                     10                   100
0                                                             1                                                         10   100 
C D






3.3.2 Wnt3A reduces the percentage MyoD positive nuclei in C2C12 myoblasts 
C2C12 myoblasts were then labelled for MyoD to help establish the mechanism of Wnt3A-
inhibited differentiation.  The myoblasts were cultured to 80% confluence on glass coverslips 
and subsequently differentiated for 24 or 72 hours in medium containing Wnt3A at0 ng/ml, 1 
ng/ml, 10 ng/ml or 100 ng/ml.  The myoblasts were then fixed with 4% paraformaldehyde, 
blocked with 5% donkey serum and incubated with anti-MyoD primary antibody.  A secondary 
antibody excited at 488nm was used to visualize primary bound anti-MyoD antibody and nuclei 
stained with Hoechst.  Images were taken using a Zeiss LSM 710 confocal microscope (Figure 
3.2A).  The percent of MyoD positive nuclei was then calculated for each treatment (Figure 
3.2B).After 24 hours, both 10 ng/ml and 100 ng/mlWnt3A had significantly (p<0.05, compared 
to 0 ng/ml) decreased the percentage MyoD positive nuclei from 5.6% (control) to 3.5%.  
Although not found to be significant, Wnt3A also appeared to decrease the percent of MyoD 
positive nuclei after 72 hours (Figure 3.2B).  While the control displayed a total of 14% MyoD 
positive nuclei,  1 ng/ml, 10 ng/ml and 100 ng/mlWnt3A treatments resulted in 6%, 5.4% and 
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3.3.3 Wnt7A does not significantly affect C2C12 myoblast differentiation 
C2C12 myoblasts were differentiated in DM containing Wnt7A (0 ng/ml, 1 ng/ml, 10 ng/ml and 
100 ng/ml) over a 5 day period.  Phase contrast images of myoblasts revealed no overt difference 
in myotube formation between the treated and untreated cells (Figure 3.3A).  Furthermore, actin 
labelling revealed little or no change in cytoskeletal structure in response to Wnt7A (Figure 
3.3B).  Expression of MyHC remained relatively constant in response to Wnt7A when compared 
to control (Figure 3.3C and Figure 3.3D). 
 
Figure 3.3 Differentiation of C2C12 myoblasts in response to Wnt7A.  A) Phase contrast images of 
differentiating myoblasts were taken after 5 days incubation with Wnt7A at 0 ng/ml, 1 ng/ml, 10 ng/ml or 100 
ng/ml.  B) The actin cytoskeletal structure was labelled with phalloidin (green) and the myonuclei with Hoechst 
(blue). C) Western blots to determine MyHC expression were carried out on lysates prepared from day 5 
differentiated myoblasts.  Alpha-tubulin was used as the internal loading control. D) Densitometry was performed 
on the blots using the ImageJ, image analysis software and MyHC levels relative to alpha-tubulin and the untreated 
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3.3.4 Wnt7A reduces the percentage MyoD positive nuclei in C2C12 myoblasts 
After 24 hours, C2C12 myoblasts treated with 1 ng/mlWnt7A showed a significant (p<0.05) 
decrease in the number of MyoD positive nuclei, dropping from 6% (control) to 4% positive 
nuclei (Figure 3.4B).  Neither the 10 nor 100 ng/mlWnt7A treatments appeared to significantly 
decrease nuclear MyoD expression (Figure 3.4B).After 72 hours of differentiation, 100 ng/ml 
Wnt7A lowered the percentage of MyoD positive C2C12 nuclei from 14% (control) to 5.65% 
(p<0.05, compared to 0 ng/ml).  Neither the 1 ng/ml nor 10 ng/ml Wnt7A concentrations 
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3.3.5 Wnt3A does not significantly decrease terminal differentiation of HSkM myoblasts 
To determine whether Wnt3A has a similar effect on donor-derived human skeletal myoblasts, 
HSkM cells were treated with differentiation medium containing Wnt3A (10 ng/ml) for 5 days.  
Media was replaced after 72 hours of differentiation.  Phase contrast microscopy and analysis of 
the actin cytoskeleton revealed little difference in myotube formation between Wnt-treated 
myoblasts and the control (Figure 3.5a and Figure 3.5B).  Western blot analysis of MyHC 
revealed an 18% drop in expression relative to control; however, this result was not seen to be 
statistically significant (Figure 3.5D).   
 
Figure 3.5 Differentiation of HSkM myoblasts in response to 10 ng/ml Wnt3A.  A) Phase contrast images of 
differentiating myoblasts were taken after 5 days incubation with Wnt3A at 0 ng/ml or 10 ng/ml.  B) The actin 
cytoskeletal structure was labelled with phalloidin (green) and the myonuclei with Hoechst (blue). C) Western blots 
to determine MyHC expression were carried out on lysates prepared from day 5 differentiated myoblasts.  GAPDH 
was used as the internal loading control. D) Densitometry was performed on the blots using the ImageJ, image 
analysis software and MyHC levels relative to GAPDH and the untreated control calculated, Data are expressed as 


































3.3.6 Wnt3A does not significantly decrease the percent of MyoD positive HSkM nuclei 
The greatest effect on C2C12 nuclear MyoD was caused by Wnt3A at 10 ng/ml and 100 ng/ml.  
Both these concentrations appeared to have similar effects and caused a greater decrease in  the 
percent of MyoD positive cells when compared Wnt7A.  HSkM myoblasts were therefore 
differentiated in medium containing 0 ng/ml or 10 ng/mlWnt3A for 24 or 72 hours and MyoD 
positive nuclei counted.  Although10 ng/mlWnt3A reduced the percentage of MyoD positive 
nuclei from 9.1% (control) to 4.8% (10 ng/ml; Figure 3.6B) after 24 hours, this result was not 
found to be significant.  Similarly, Wnt3A had no significant effect on nuclear MyoD levels after 
72 hours of differentiation (Figure 3.6D).  After 72 hours of differentiation the control myoblasts 
displayed 17.2% MyoD positive nuclei while the Wnt3A-treated cells had 15.8% MyoD positive 





Figure 3.6 MyoD positive HSkM nuclei after incubation with Wnt3A.  HSkM myoblasts were treated with 
differentiation medium containing Wnt3A at 0 ng/ml or 10 ng/ml.  After A) 24 hours or C) 72 hours of 
differentiation, the myoblasts were fixed and labelled for viewing under a Zeiss LSM 710 confocal microscope.  Co-
localization of MyoD (green) and the Hoechst nuclear stain (blue) indicates myoblast commitment to differentiation.  
MyoD positive nuclei are enclosed by red circles.  The percent of MyoD positive nuclei was calculated for the B) 24 
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The successful growth and repair of muscle tissue relies heavily on the effective differentiation 
and fusion of myoblast cells.  A number of signalling molecules and factors regulate this process 
and include the myogenic regulatory factor MyoD (Moran et al., 2002; Holterman and Rudnicki 
2005).  MyoD is a basic helix-loop-helix transcription factor which is up-regulated during the 
initial stages of differentiation and accumulates in the nucleus, initiating the expression of 
essential muscle proteins.  One such protein is the MyHC subunit which makes up part of the 
contractile myosin protein.  In our study we wished to determine the effect of Wnt3A and 
Wnt7A on the differentiation of mouse C2C12 and human donor-derived myoblasts.  Expression 
of nuclear MyoD was used to verify the onset of differentiation while MyHC Western blots were 
used to determine the degree of differentiation.   
Terminal differentiation of myoblasts was determined using phase contrast microscopy (myotube 
alignment and formation), confocal microscopy (expression of actin during differentiation) and 
Western blotting (MyHC expression).  C2C12 myoblasts were differentiated in Wnt-containing 
DM for a total of 5 days.  By examination of phase contrast images, (Figure 3.1A and Figure 
3.3B), it was apparent that Wnt3A decreased the number of myotubes produced.  With each 
increasing concentration of Wnt3A, there was a further decrease in myotube formation.   
Wnt7Ahowever appeared to have no effect on myotube formation (Figure 3.3A).  These results 
were supported by confocal microscopy images of the actin cytoskeletal structure of the 
myoblasts (Figure 3.1B and 3.3B).  Myoblasts treated with Wnt3A were seen to have less 
cytoskeletal actin.  Wnt7A also appeared to have no effect on actin formation.  Western blots 
determined that the MyHC levels of cells treated with Wnt3A decreased with each increasing 
concentration of Wnt (Figure 3.5D).  This trend was not seen in the Wnt7A treated cells (Figure 











Table 3.1 Relative MyHC levels of Wnt treated C2C12 cells  
Wnt concentration  (ng/ml) Relative MyHC levels  















Nuclear MyoD in differentiating C2C12 myoblasts was analysed to try determine a mechanism 
of effect of Wnt signalling.  C2C12 myoblasts were differentiated in Wnt-containing medium for 
24 or 72-hours and viewed using a LSM confocal microscope to determine the percentage MyoD 
positive nuclei.  A summary of these results can be seen in Table 3.2. 
Table 3.2 Percent of MyoD positive C2C12 nuclei in response to Wnt3A or Wnt7A 
Wnt concentration (ng/ml) Percent MyoD positive nuclei (% positive, n=3,  *p<0.05) 
Wnt3A 24-hour 72-hour 
0 5.6 13.9 
1 4.2 5.9 
10 3.6* 5.4 




0 5.6 13.9 
1 4.1* 8.5 
10 5.1 7.0 
100 4.8 5.6 
Our results suggest that both Wnt3A and Wnt7A decrease the percentage MyoD positive nuclei 
during the early stages of C2C12 differentiation with this effect being most pronounced in the 
Wnt3A-treated cells. The reduction in response to Wnt7A was unexpected as a reduction in the 
percent of MyoD positive nuclei would logically be accompanied by inhibited differentiation.  
However, only Wnt3a was seen to inhibit this process. 
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Wnt3A was seen therefore to reduce both the percentage MyoD positive nuclei and the degree of 
terminal differentiation of C2C12 myoblasts.  It is likely that Wnt3A signalling down-regulates 
nuclear MyoD expression which in turn decreases differentiation.  AlthoughWnt7A (1 ng/ml) 
was also seen to reduce the percent of MyoD positive nuclei, the effect was not translated into a 
decrease in terminal differentiation.  A possible explanation for this could be the functional 
redundancy between MyoD and Myf5.  Myf5 is able to compensate in part for the absence of 
MyoD.   This has been observed in mice lacking a functional MyoD gene which produce four-
fold higher levels of Myf5, but have no physical abnormalities (Megeney et al.,1996).  Similarly, 
mice lacking a functional MyoD gene displayed four-fold higher levels of Myf5.  Elimination of 
both the MyoD and Myf5 genes resulted in severe abnormalities and no myoblasts being formed 
(Ustanina et al., 2007).  It is possible that Wnt3A inhibits the expression of both MyoD and 
Myf5, thus inhibiting differentiation. Wnt7A on the other hand may inhibit MyoD and not Myf5 
and therefore had no effect on differentiation.   In our research, Myf5 Western blots were run, 
but were unsatisfactory.  It is suspected that weak, non-specific binding of the antibody resulted 
in poor blots.  In future work we intend to use mRNA analysis to determine Myf5 expression 
levels.  No other publications have been found that investigate the effect of Wnt3A or Wnt7A on 
MyoD or Myf5 expression during myoblast differentiation.    
Inhibitors of differentiation (Id1, Id2 and Id3) form heterodimers with bHLH transcription 
factors such as MyoD, Myf5 and Myogenin, preventing DNA binding and myoblast 
differentiation (Liu et al.,2002; Pammer et al.,2004).  It has previously been reported that Wnt3A 
inhibits the differentiation of C2C12 myoblasts by the up-regulation of the inhibitor of 
differentiation 3 (Id3) (Cathy et al.,2011; Zhang et al.,2012).  Id3 is known to form heterodimers 
with MyoD which prevents the expression of muscle specific proteins such as myogenin and 
MyHC (Liu et al.,2002).  It is likely that Wnt3A inhibits the production of MyoD and up-
regulates the expression of Id3 in C2C12 myoblasts, thus inhibiting differentiation.  Wnt7A has 
not been shown to up-regulate Id3 and may simply have an inhibitory effect on MyoD as 
demonstrated in our results.   
 
During the course of this study we noticed the relatively low percentage of MyoD positive nuclei 
in the control C2C12 nuclei when compared to other published works.  No contamination of the 
cells was observed; however it is possible that during cell-stock preparation, C2C12 myoblasts 
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were cultured post-confluence (above 90% confluence).  Culturing these cells post-confluence is 
known to reduce their myogenic capacity.  This may have resulted in the lower levels of nuclear 
MyoD.  Being the only available batch of C2C12 myoblasts at the time, these cells were used 
throughout the MyoD testing.  Despite these slightly lower levels of MyoD, the myoblasts were 
still able to differentiate, albeit with a lower efficiency. 
 
Wnt3A was seen to have the greatest effect on C2C12 differentiation, with 10 ng/ml and 100 
ng/ml concentrations reducing differentiation to similar levels.  In the interest of preserving Wnt 
and optimising the usage of HSkM myoblasts, these human derived cells were treated with 10 
ng/mlWnt3A.  Although Wnt3A appeared to reduce MyoD positive HSkM nuclei after 24 hours 
of differentiation (Table 3.3), this effect was not significant.  Furthermore, the effect was lost 
after 72 hours (Table 3.3).  It was noted that the HSkM cells did not adhere to the glass 
coverslips as strongly as the C2C12 myoblasts.  This accounts for the lower number of cells 
visible in the confocal images as more cells had been washed away during the preparation steps.   
Table 3.3 Percent MyoD positive HSkM nuclei in response to Wnt3A 
Wnt3A concentration (ng/ml) Percent MyoD positive nuclei (% positive, n=3) 
 24-hour 72-hour 
0 9.1 17.2 
10 4.8 15.8 
 
Interestingly after 24 hours, the percent of MyoD positive HSkM nuclei had dropped 46% when 
compared to control (C2C12 cells displayed a 24% drop after the same treatment).  After 72 
hours however, the percent of MyoD positive HSkM nuclei had dropped by only 8% in response 
to Wnt3A.  This result suggested that HSkM differentiation may not be as severely affected as 
that for C2C12 myoblasts which saw a 61% drop in MyoD positive nuclei relative to the control.  
These C2C12 cells displayed severely impaired differentiation with an 88% drop in MyHC 
levels.  The Wnt3A-treated HSkM cells only displayed an18% drop in MyHC levels after 5 days 
of differentiation.  In addition, both phase contrast microscopy and confocal microscopy revealed 
little morphological change in the HSkM cells.  Wnt3A was expected to have a greater effect on 
HSkM differentiation judging by the severe inhibition of C2C12 myotube formation, and the fact 
that human and mouse Wnt3A share ≈98% identity.  It is possible that the difference in response 
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is due to varying Fz profiles between the cell types or the fact that only one Wnt3A 
concentration was used.  Future HSkM work would need to include a wider range of Wnt 
concentrations.    
 
In summary, Wnt3A but not Wnt7A caused a severe decrease in C2C12 myoblast differentiation.  
This could partly be explained by lowered expression of MyoD, however other factors such as 
Id3 and Myf5 are likely to play a part.  Human myoblasts did not respond as overtly to Wnt3A as 
did the mouse C2C12 myoblasts.  This could be as a result of Fz receptor profiles or a dose-






















Skeletal muscle myoblasts are the quintessential muscle stem cells and are responsible for the 
growth and repair of muscle tissue.  The success of muscle growth and repair is determined 
largely by a) the velocity at which the myoblasts reach the site of injury, b) the rate at which the 
myoblasts proliferate within the wound area and c) the degree to which the cells differentiate and 
fuse to form/repair the muscle tissue.  It has recently been established that the Wnt family of 
secreted proteins play an important role in tissue development.  In our study we wished to 
evaluate the effects of recombinantWnt3A and Wnt7A on the migration, proliferation and 
differentiation of murine C2C12 and human donor-derived skeletal muscle myoblasts in vitro.  
The main findings of our research are summarized in Tables 4.1 and 4.2.  All values are 
expressed as a decrease or increase relative to untreated control. 
Table 4.1 The effects of Wnt3A and Wnt7A on the migration, proliferation and 

























10 ↑5.9% ↑20.1%* ↑24.8%* ↓7.1% ↓39.2%* ↓47.3% ↓88.3% 
100 ↑12.7%, ↑12.7% ↑21.6%* ↓1.4% ↓38.0%* ↓48.5% ↓94.3% 
 
Wnt7A 
       
1 ↑9.8% ↑11.6% ↑12.7% ↑2.6% ↓28.5%* ↓25.5% ↑4.1% 
10 ↑10.8% ↑25.4%* ↑19.9%* ↓14.3% ↓9.4% ↓34.9% ↑18.4% 
100 ↑19.6% ↑15.9% ↑13.4%* ↓10.2% ↓15.0% ↓53.8% ↑1.7% 
Table 4.2 The effects of Wnt3A and Wnt7A on the migration, proliferation and 



























       
100 - - - ↓3.7% - - - 
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By examination of the C2C12 wound closure values, it is apparent that Wnt3A increased the rate 
of myoblast migration.  Confusingly, the only decrease in migration was seen at the 3 hour time 
point for the 1 ng/ml concentration.  By 5 hours however, the rate of wound closure had 
increased beyond that of the control.  It is possible that the cells react to Wnt3A in a dose 
dependent manner and the initial low concentration of Wnt3A causes a slight delay in myoblast 
migration.  Of all the Wnt3A concentrations, the 10 ng/ml treatment had the greatest pro-
migratory effect followed by 100 ng/ml.  Our findings were seen to contradict those of Tanaka et 
al. (2011) who showed the migration of Wnt3A-expressing C2C12 myoblasts to be reduced.  In 
our study, C2C12 myoblasts were treated with Wnt protein after ‘wounding’ and were given 7 
hours to migrate.  We wished to simulate an up-regulation of Wnt in response to an injury rather 
than having an over-expressing cell line that would constantly be exposed to the signalling 
protein.  Constant exposure to Wnt could quite possibly result in the myoblasts changing their Fz 
receptor profile as has been shown in HELA cells (Mukai et al.,2010).  HELA cells are able to 
recycle Fz in response to extracellular Wnt levels and thus limit the rate of Wnt binding and 
signalling.  Furthermore, the concentration at which Wnt3A was secreted by Tanaka’s myoblasts 
(Tanaka et al.,2011) was not stipulated and further complicates direct comparison with our 
findings.Wnt3A (10 ng/ml) was also seen to increase the migration of HSkM cells.  When 
compared to the C2C12 results, it would seem that the HSkM cells responded quicker to Wnt3A 
with a larger 3 hour closure value.  On the other hand, Wnt3A seemed to have an increasingly 
pro-migratory effect on the C2C12 cells over the 7 hour period.  This result appears to be novel 
as no publications could be found involving Wnt and HSkM migration. 
In addition to Wnt3A, Wnt7A was seen to increase the migration of C2C12 cells.  Wnt7A 
concentrations tested (10 ng/ml and 100 ng/ml) significantly increased the percent wound closure 
at the 5 and 7 hour time points.  As with Wnt3A, the 10 ng/mlWnt7A concentration was seen to 
have the greatest effect on migration.  Once again, these findings appear to be novel.  This result 
may be of particular interest as Wnt7A is already being studied as a potential treatment for 
Duchene’s muscular dystrophy as it has been found to expand the satellite cell pool in vivo (Le 
Grand et al.,2009, von Maltzahn et al.,2012).     
Neither Wnt3A nor Wnt7A were seen to have any significant effect on the proliferation of 
C2C12 or HSkM myoblasts.  Although not significant, the most noticeable effects were caused 
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by 10 ng/ml and 100 ng/mlWnt7A treatments which caused a 14.3% and 10.2% decrease in 
C2C12 cell number relative to control respectively.  Wnt7A at 100 ng/ml was also seen to 
decrease the proliferation of HSkM myoblasts (3.7% decrease).These proliferation findings were 
unexpected as Wnt7A has been linked with the maintenance of a healthy satellite cell population.  
Studies carried out by Bentzinger et al. (2013) and von Maltzahn et al.,(2012) have shown 
Wnt7A to increase satellite cell number in vivo.  It has been suggested by Bentzinger et al. 
(2013) that it is in fact Wnt7A in conjunction with fibronectin that regulates cell number.  The 
absence of fibronectin in our in vitro study may account for the differing results.   
In terms of differentiation, both Wnt3A and Wnt7A were seen to decrease the percentage of 
MyoD positive C2C12 nuclei.  Wnt3A and Wnt7A concentrations (1 ng/ml, 10 ng/ml and 100 
ng/ml) reduced this percentage after 24 and 72 hours of treatment, however, only Wnt3A was 
observed to inhibit differentiation.  Differentiation was measured using Western blots sensitive 
for the muscle specific contractile protein MyHC.  Wnt3A at 1 ng/ml, 10 ng/ml and 100 ng/ml 
was seen to drastically reduce C2C12 differentiation resulting in a 39%, 88% and 94% reduction 
in MyHC levels relative to control respectively (after 5 days of differentiation).  This was 
expected as previous studies have shown Wnt3A to reduce C2C12 myoblast differentiation via 
the up-regulation of the inhibitor of differentiation 3 (Id3) (Cathy et al.,2011; Zhang et al.,2012).  
Id3 is known to form heterodimers with MyoD, inhibiting differentiation (Cathy et al.,2011; 
Zhang et al.,2012).Wnt3A (10 ng/ml) also decreased the percent of MyoD positive HSkM 
nuclei.  This reduction however was not as drastic as that seen for the C2C12 cells.  HSkM 
myoblasts treated with 10 ng/ml Wnt3A did not display significantly altered myotube formation 
(using Western blots and phase contrast microscopy).   
Despite reducing the percentage of MyoD positive C2C12 nuclei, Wnt7A did not decrease 
terminal differentiation.  In fact, Wnt7A may encourage terminal differentiation with the 10 
ng/ml treatment increasing MyHC levels by 18% relative to control.  These increases were 
minimal however and were not seen to be significant (p<0.05).  It is suspected that the functional 
redundancy between MyoD and Myf5 may be a reason for the relatively unchanged MyHC 
levels in the Wnt7A treated cells, despite the decrease in nuclear MyoD.  In the absence of 
MyoD, levels of Myf5 in primary culture murine myoblasts have been shown to increase 5-fold, 
leaving differentiation relatively unaffected (Megeney et al.,1996).  It is possible that Wnt7A 
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affects MyoD while having no effect of Myf5 and thus allows for successful differentiation.  
Wnt3A on the other hand may inhibit the expression of Myf5 and up-regulate Id3 resulting in 
impaired differentiation.  It is also possible that Wnt3A has no effect on Myf5 at all and 
inhibition is attributed to Id3.  Myf5 Western blots were unsuccessful and so the levels of the 
MRF cannot be commented on.  In future work we wish to evaluate levels of Myf5 using mRNA 
analysis.  The effect of Wnt7A on Id proteins has not been documented and it is possible that this 
Wnt has no effect on Id expression and thus no inhibitory effect.     
Wnt signalling is extremely complex with the rate and type of Wnt signalling being highly 
dependent on a number of factors.  These factors include the type and concentration of Wnt, Fz 
and co-receptor profile as well as ECM and serum factors.  Our research and indeed most in vitro 
experimentation cannot always accurately mimic the in vivo environment.  Although our in vitro 
findings should not be overlooked, future work should include factors to mimic the in vivo 
environment more closely and hopefully understand the role of the Wnt proteins in myogenesis 
more fully.  Testing could potentially include incubating of myoblasts with Wnt while cultured 
on different ECM factors in order to test Wnt-ECM interactions.  In this way we can explore the 













APPENDIX I: CONFERENCE ATTENDANCE 
______________________________________________________________________________ 





APPENDIX II: BASIC LOCAL ALIGNMENT SEARCH TOOL 
_________________________________________________________________________ 
All protein alignments were carried out using the NCBI Basic Local Alignment Search Tool 
(BLAST).   
A2.1 Alignment of human and mouse Wnt3A 
Query: Mouse Wnt3A – Protein databank accession number: P27467.1 
Subject:  Human Wnt3A – Protein databank accession number: NP_149122 
 
A2.2 Alignment of human and mouse Wnt7A 
Query: Mouse Wnt7A – Protein databank accession number:  NP_033553.2 




APPENDIX III: ANTIBODY DILUTIONS 
______________________________________________________________________________ 
A3.1 Confocal microscopy and Western blot antibody dilutions 
Table A3.1 Antibody dilutions 




Mouse monoclonal anti-Vinculin 
(SIGMA, cat.129K4849, USA)  
1/1000 
 
Goat polyclonal anti-Rock-2     




Rabbit polyclonal anti-MyoD (Santa 
Cruz, cat.sc-760,  USA)   
1/100 
 
Donkey anti-mouse Dylight 488 (Jackson 
Immunoresearch, cat.94650, USA)  
1/1000  
 
Donkey anti-goat Cy5 596nm (Jackson 




Donkey anti-rabbit Dylight 488 (Abcam, 
cat.ab96919, UK) 
1/1000 
   




Rabbit polyclonal anti-GAPDH (Cell 
Signalling, cat.21185, USA) 
1/4000 
 
Mouse monoclonal anti-α-tubulin 
(Santa Cruz, cat.sc-5286, USA) 
1/400 
Donkey anti-mouse IgG  
(Abcam, cat.ab96857, UK) 
1/4000 
 




Donkey anti-mouse IgG  













APPENDIX IV: PROTEIN LYSATE PREPARATION AND SDS-PAGE 
_________________________________________________________________________ 
A4.1 Lysate preparation  
Cells cultured in 6-well plates were detached by treatment with 1 ml trypsin (5 minutes) and 
transferred to 15ml falcon tubes.  The activity of trypsin was neutralized by the addition of 1ml 
GM to each falcon tube.  The tubes were then spun in a bench-top centrifuge (MRC; Polychem 
Supplies) at 100g x 5 minutes.  The supernatant was discarded and the pellet re-suspended in 1 
ml PBS.  The cells were then spun again at 100g x 5 minutes.  This PBS re-suspension and 
centrifugation was repeated two further times.  After the final centrifugation step, the pellets 
were re-suspended in 45µl RIPA buffer (Sigma, cat.R0278) containing 1µl protease inhibitor 
cocktail (Sigma, cat.P8340) and placed on ice for 1 hour.  The cells were then sonicated at 
setting 13 (VirSonic60, Polychem supplies) and separated into 15µl and stored at -20°C in 15 µl 
aliquots.   
 
A4.2 SDS-PAGE 
A4.2.1 Bradford assay 
A total of 1µl lysate sample was added to 99µl of PBS and 900µl Bradford reagent (SIGMA, 
cat.B6916, USA).  The solutions were mixed thoroughly, given 2 minutes to develop and then 
transferred into plastic cuvettes (Optima Scientific, cat.2711110).  Each concentration was set in 
triplicate.  Absorbance was measured at 595nm (Ultrospec II E, LKB Biochrom) and the protein 
concentrations calculated using a standard calibration curve (Figure A5.1).  The standard curve 
was developed using bovine serum albumin (Roche, cat.10735086001).     
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Figure A4.1 Bradford protein standard curve.  Bovine serum albumin was diluted to a concentration of 1mg/ml 
using PBS.  A range of bovine serum protein (0-40µg) was added to 900µl of Bradford reagent and made up to 1 ml 
using PBS.  Solutions were vortexed and allowed to develop for 5 minutes.  Absorbance readings were taken in at 
595nm.   
 
A4.2.2 SDS-PAGE reagents 
Monomer solution (30% (m/v) acrylamide, 2.7% (m/v) Bis-acrylamide):  Acrylamide (73 g) and 
Bis-acrylamide (2 g) were made up to 250ml in distilled water, filtered though Whatmans 
number 2 filter paper and stored in an amber glass bottle at 4°C. 
 
4 x Running gel buffer (1.5M Tris-HCL, pH 8.8):  Tris (45.37g) was dissolved in 200ml distilled 
water, titrated to pH 8.8 with HCL and made up to 250ml.  Filtered through Whatmans number 2 
filter paper and stored in a plastic bottle at 4°C.   
 
4 x Stacking gel buffer (500 mM Tris-HCL, pH 6.8):  Tris (3g) was dissolved in 50ml distilled 
water and titrated to pH 6.8 with HCL.  The buffer was stored in a plastic bottle at 4°C.      
 
SDS stock solution (10% m/v): SDS (5g) was dissolved in 50ml distilled water and filtered 
through Whatman’s No.1 filter paper and stored in a glass bottle at room temperature.        
 























Ammonium persulfate initiator (10% m/v): Ammonium persulfate (0.1g) was dissolved in 1ml 
distilled water.  Initiator was prepared fresh before use and stored at room temperature for no 
longer than 2-3 hours.   
Reducing sample treatment buffer (125mM Tris-HCl, pH 6.8):  4ml of 10% SDS stock solution, 
2.5ml of 4x stacking gel buffer and 1ml of 2-mercaptoethanol were mixed together, titrated to 
pH 6.8 and made up to 10ml with distilled water.  The treatment buffer was stored in a plastic 
container at room temperature.  
Tank buffer(250mM Tris-HCl, pH 8.3): Tris (3g), glycine (14.4g) and 10ml of 10% SDS stock 
solution were mixed into 900ml of distilled water, titrated to pH 8.3 and made up to 1000ml.     
All gels consisted of a 4% (m/v) polyacrylamide stacking gel and 12.5% (m/v) polyacrylamide 
according to Laemmeli’s protocol (Laemmli, 1970).  Volumes of the various components in each 
gel are given in Table A4.3. 
Table A4.1 Stacking and running gel composition 
Reagents Stacking gel (4%) Running gel (12.5%) 
Monomer Solution 0.94ml 6.25ml 
4x Running Gel Buffer - 3.75ml 
4x Stacking Gel Buffer 1.75ml - 
10% SDS Stock Solution 70µl 150µl 
Distilled Water 4.3ml 4.75ml 
Initiator  35µl 75µl 












APPENDIX V: WESTERN BLOT 
______________________________________________________________________________ 
A5.1 Reagents 
Blotting buffer:Tris (6.05g) and glycine (14.4g) were dissolved in 700ml distilled water followed 
by the addition of 200ml methanol.  The solution was titrated to pH 8.8 and made up to 
1000ml.1ml of 10% (m/v) SDS was added and the solution.  Blotting buffer was made up fresh 
before use. 
Ponceau: Ponceau S. (0.1g)(SIGMA, cat.P3504, USA) was dissolved in 1ml of 100% (v/v) 
acetic acid and made up to 100ml with distilled water.  The Ponceau S stain was stored in a 
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